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ABSTRACT
Quality of Life and Clinical Outcomes in Type 2 Diabetes Patients at the Primary
Care Clinics of the West Virginia University Hospital

Murali Sundaram

This study examines relationships between quality of life (QoL) and clinical
outcomes, specifically A1C, in Type 2 diabetes patients. Type 2 diabetes patients at the
outpatient clinics of a university hospital completed a generic QoL measure (SF-12) and
a diabetes-specific QoL measure (Audit of Diabetes Dependent Quality of Life
(ADDQoL)). A cover letter signed by the patient's provider was sent with a mail out
questionnaire. Patient reported data was merged with a retrospective collection of his/her
clinical and utilization data, including A1C, from electronic medical records. A Charlson
comorbidity score, diabetes complications score, BMI, and number of ER and hospital
visits were also calculated. Usable response rate was 44.3% (n = 385). Respondents were
57.1% female, 93.8% Caucasian, and 64.1 % were in the 40-69 age range; 49.1 % were
on oral medications only, 31.7% were on oral medications and insulin, and 9.4%, on
insulin only. Mean A1C of respondents was 7.2 (+1.4), mean diabetes duration was 10.2
(+9.1), and 62.1% were obese (BMI>30). Patients were dichotomized into glycemic
control levels based on the ADA recommended A1C level <7.0, versus > 7.0. Cronbach's
alphas for the ADDQoL, PCS (SF-12 Physical Component Score), and MCS (SF-12
Mental Component Score) were 0.92, 0.92, and 0.88, respectively. Only ADDQoL scores
showed significant correlation with A1C (r= -0.19, p < 0.000). Hierarchical regression
models were used to separately explain ADDQoL, PCS, and MCS scores, using A1C as
the primary independent variable, and controlling for demographics and clinical variables
including comorbidities and complications. A1C was not a significant predictor in any
regression model, although univariate analyses indicated significantly lower ADDQoL
and SF-12 PCS in the group with A1C > 7.0, and in the group with one or more diabetes
complications. Obesity was a significant predictor in models explaining only the PCS and
MCS scores. These results support complementary use of generic and disease-specific
QoL measures in Type 2 diabetes populations. Patient's perceptions of their own life may
differ from what a biomedical measure like A1C suggests.
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CHAPTER ONE: INTRODUCTION

Part One – Diabetes Overview

Prevalence of Diabetes and its Cost Implications
The World Health Organization (WHO) states that a diabetes epidemic is
underway. While an estimated 30 million people worldwide had diabetes in 1985, this
number had increased to 135 million by 1995 (WHO, 2002). The latest WHO figure for
the number of people with diabetes worldwide in 2000 was estimated at 177 million and
is projected to increase to at least 300 million by 2025. The number of annual deaths
attributed to diabetes was previously estimated at just over 800,000 worldwide (WHO,
2002), but this may be underestimated. The WHO estimates a more likely figure would
be around four million diabetes-related deaths per year, and represents nine percent of the
total deaths around the globe (WHO, 2002). With an increasing number of patients with
diabetes worldwide, the disease will require a growing proportion of funding from
national health care budgets. Diabetes is projected to become one of the world’s main
disablers and killers within the next twenty-five years (WHO, 2002).
Diabetes is the sixth leading cause of death by disease in the U.S. (Kochanek and
Smith, 2004). In 2002, approximately 73,119 deaths were attributable to diabetes, with a
death rate of 25.4 per 100,000 people in the U.S. (Kochanek and Smith, 2004). One
million new cases of diabetes are diagnosed per year in the U.S. among people aged 20
years or older (NDIC, 2003). In 2002, annual direct medical expenditures totaling $92
billion were attributed to diabetes (compared to $44 billion in 1997) and were comprised
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of $23.2 billion for diabetes care, $24.6 billion for chronic diabetes-related
complications, and $44.1 billion for excess prevalence of general medical conditions
(Hogan, Dall & Nikolov, 2003). The total health care cost of a person with diabetes in the
U.S. was found to be between two and three times the costs for people without the
condition (WHO, 2002). Diabetes is associated with higher rates of lost work time,
disability, and premature mortality, and imposes a significant burden to families and
friends of those with diabetes as well (Hogan, Dall & Nikolov, 2003). The economic
expense to the U.S. economy, due to the indirect costs of lost productivity resulting from
lost workdays, restricted activity days, permanent disability, and mortality due to diabetes
in 2002 is conservatively estimated to be $40 billion. Therefore, the resulting total direct
and indirect costs estimated at $132 billion in 2002 comprise one out of every ten health
care dollars spent in the U.S. This forms a tremendous national economic burden (Hogan,
Dall & Nikolov, 2003).
The costs of diabetes are not only a financial problem. Intangible costs (pain,
anxiety, inconvenience, generally lower quality of life, and others) also have great impact
on the lives of patients and their families and are the most difficult to quantify (WHO,
2002). In addition, diabetes is associated with a higher risk for heart disease, blindness,
kidney failure, extremity amputations, and other serious chronic conditions. Overall, the
risk for death among people with diabetes is about two times that of people without
diabetes (NDIC, 2003).
The 2002 Behavioral Risk Factor Surveillance System (BRFSS) revealed an
estimated diabetes prevalence of 10.2% among West Virginia (WV) adults (CDC, 2002).
WV was ranked second in prevalence, and is among only two states and territories in the
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U.S. with greater than 10% prevalence, for the disease (CDC, 2002). Diabetes prevalence
has been recorded consistently higher in WV than in the U.S. through most of the 1990s
(WV Department of Health and Human Resources [WVDHHR], 2003). Diabetes was the
sixth leading cause of death in WV, ranking second among the states and territories of the
U.S. in diabetes-related deaths (WVDDHR, 2003). There are other factors contributing to
the high rate of diabetes in WV. The prevalence of obesity in WV has also been
consistently higher than that in the U.S. (WVDHHR, 2002). In 2002, the WV prevalence
rate of obesity was 27.6%, compared to 22.2% nationally (CDC, 2002). Further
complicating this trend is the fact that a large percent of West Virginians live in very
rural areas, with limited access to healthcare and low education and income levels
(WVDDHR, 2001).
Diabetes is a chronic disease associated with complications and other comorbid
conditions that add to the burden of diabetes. Some of the more significant complications
resulting from the inefficient management of diabetes are eye disease (blindness,
retinopathy), kidney disease (nephropathy, end stage renal disease), and nervous system
damage (neuropathy, foot ulcers), among others. Heart disease is the leading cause of
diabetes-related deaths; the risk of heart disease is two to four times higher in persons
with diabetes (CDC, 2003). The risk of stroke is two to four times greater, and an
estimated 73% of persons with diabetes have hypertension (CDC, 2003). Diabetes is also
the leading cause of adult blindness and end stage renal disease accounting for 44% of
new cases of kidney failure (CDC, 2003). Approximately 60-70% of persons with
diabetes have neuropathies; severe forms of diabetic nerve disease are a major
contributing cause of lower-extremity amputations (CDC, 2003). Other less common
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complications associated with diabetes include periodontal disease, complications of
pregnancy and acute life-threatening events such as diabetic ketoacidosis and
hyperosmolar coma. People with diabetes are also more susceptible to many other
illnesses and once they acquire these illnesses, their prognoses worsens (CDC, 2003).

Diabetes and its Types
Diabetes mellitus consists of a group of diseases characterized by high levels of
blood glucose resulting from defects in insulin production, insulin action, or both.
Types of diabetes
Type 1 diabetes. Type 1 diabetes was previously called insulin-dependent diabetes
mellitus (IDDM) or juvenile-onset diabetes. This form of diabetes usually strikes children
and young adults, who need several insulin injections a day or an insulin pump to
survive. Type 1 diabetes may account for five to ten percent of all diagnosed cases of
diabetes (CDC, 2003). Risk factors for Type 1 diabetes include autoimmune, genetic, and
environmental factors.
Type 2 diabetes. Type 2 diabetes was previously called non-insulin-dependent
diabetes mellitus (NIDDM) or adult-onset diabetes. Type 2 diabetes may account for
about 90 to 95 percent of all diagnosed cases of diabetes (CDC, 2003). Type 2 diabetes is
most often associated with older age, obesity, family history of diabetes, prior history of
gestational diabetes, impaired glucose tolerance, physical inactivity, and race/ethnicity.
Type 2 diabetes is increasingly being diagnosed in children and adolescents. It is treated
using a class of drugs known as oral hypoglycemic agents (OHAs), which include
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sulfonylureas, biguanides, and some newer agents like thiazolidinediones, meglitinides,
and alpha-glucosidase inhibitors.
Gestational diabetes. Gestational diabetes is a form of glucose intolerance that is
diagnosed in some women during pregnancy. It is also more common among obese
women and women with a family history of diabetes. During pregnancy, gestational
diabetes requires treatment to normalize maternal blood glucose levels to avoid
complications in the infant. After pregnancy, five to ten percent of women with
gestational diabetes are found to have developed type 2 diabetes. Women who have had
gestational diabetes have a 20 to 50 percent chance of developing diabetes in the next
five to ten years (CDC, 2003).
Other types of diabetes result from specific genetic conditions such as maturityonset diabetes of youth, genetic defects of the beta cells of the pancreas, and genetic
defects in insulin action. Other causes include other illnesses, drugs that impair insulin
secretion, malnutrition, infections, and certain viruses that are associated with beta cell
destruction and endocrinopathies. Such types of diabetes may account for 1 to 5 percent
of all diagnosed cases of diabetes (CDC, 2003).

Part Two – Quality of Life and Diabetes

Conceptualizing Quality of Life and Health Related Quality of Life
In 1948, the World Health Organization defined health from a multi-dimensional
perspective. Absence of disease and infirmity on one hand, but also the presence of
physical, mental and social well being, was regarded as constituting health. In the
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following years, there has been great interest in studying the effect of psychosocial
factors on health outcomes. Quality of life (QoL) is being referred to as a
multidimensional construct that comprises the individual’s subjective perception of
psychological, social, and physical well being (Snoek, 2000). The key aspects to note are
that QoL encompasses multiple domains that influence overall QoL in their own way and
that it should be based on the patient’s self-report rather than the health care
professional’s point of view (Snoek, 2000). Quality of Life, a patient self-reported
measure, can be differentiated from objective physical health status that is assessed by
physicians’ reports of symptoms and/or the presence of complications (Rubin & Peyrot,
1999). Quality of life comprises the individual’s subjective perception of physical,
emotional and social well being, including both a cognitive component (like satisfaction)
and an emotional component (like happiness) (Rubin, 2000; Rubin & Peyrot, 1999).
Testa (2000) states that QoL is not a static measure, but is a health assessment
approach that focuses on patient reports, feelings, and expectations. By QoL, the
reference is not only to the health aspects of life, but also to the broadest range of human
experiences (Polonsky, 2000). Narrowing down the scope of QoL to aspects of
functioning directly related to disease, medical treatments, or both, the term Health
Related Quality of Life (HRQOL) was introduced, which concerns with how overall QoL
happens to be influenced by health and disease (Polonsky, 2000). In measuring the
various dimensions of health, the physical, psychological and social aspects to represent
the complete spectrum of life functioning are considered.
There is now increasing recognition that the impact of chronic illnesses and their
treatments must be assessed for their influences on QoL in addition to more traditional
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measures of medical outcomes, such as morbidity and mortality (Jacobson, De Groot &
Samson, 1994). Hareendran (2004) summarizes the value that patient reported outcomes
like QoL can add to the evaluation of new treatments: They are key measures of
treatment outcomes when there are no objective markers of symptoms and no objective
markers of the impact of symptoms. They also complement traditional endpoints to
evaluate the significance of a treatment effect from a patient’s perspective. Information
on QoL outcomes can facilitate patients’ involvement in treatment decision-making.
Finally, Hareendran (2004) states that QoL outcomes can provide guidance for health
care decision making by enabling a better understanding of the burden of illnesses and in
making healthcare allocation decisions.
Quality of Life has been recognized as one of the important goals for public
health in the report of Healthy People 2010, which is a set of health objectives for the
U.S. to achieve over the first decade of the 21st century. Healthy People 2010 presents
467 objectives to improve the health of Americans by the year 2010. The first goal of
Healthy People 2010 is “to help individuals of all ages increase life expectancy and
improve their quality of life” (U.S. Department of Health and Human Services, 2000).
The year 2010 goals for diabetes care in WV focus on the following challenges:
‘increasing the demand for better diabetes care through public awareness; increasing
early detection of Type 2 diabetes; improving management of diabetes care; increasing
the collection of statewide diabetes data; and monitoring and evaluating the effectiveness
of diabetes care statewide’ (WVDHHR, 2001). The stated overall main goal in the report
is to increase the ‘quality of life’ for persons with diabetes living in WV. However,
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‘quality of life’ from the perspective of a government public health document may be
interpreted as a more general indicator of the quality and standard of life of people.

Patient-Reported Outcomes Like Quality of Life in Persons With Diabetes
Landmark studies like the Diabetes Control and Complications Trial (DCCT) and
the United Kingdom Prospective Diabetes Study (UKPDS) showed that maintaining
blood glucose levels as close to normal as possible slows the onset and progression of
some of the complications caused by diabetes, like eye, kidney, and nerve conditions
(DCCT Research Group, 1993 and UKPDS Group, 1998). As a result of the
dissemination of these study findings into clinical practice by organizations like the
American Diabetes Association (ADA), glycemic control became the essential outcome
focus of diabetes treatment in clinical practice.
Medical research and care is becoming more patient-focused, and there is
increasing appreciation of patient-reported outcomes, or the patient’s perspective on
health, disease, and medical treatments (Polonsky, 2000). Diseases can affect QoL of
people in different ways depending on the aspects of life that are compromised due to the
presence of that disease. The management of diabetes itself has a major impact on
people’s lives, in terms of physical and psychological well being. This is due to the
considerable demands imposed by current care practices on persons with diabetes.
Complications associated with diabetes have been found to substantially increase the
morbidity and mortality of affected persons and to reduce their QoL (ADA, 2001).
Polonsky (2000) states that the true impact of a successful medical intervention can
reflect the degree to which it has a positive influence on a patient’s health and well being.
Applying a similar thought in the area of diabetes care, there is a suggestion to not limit
8

the goals of diabetes care only to strict glycemic control, but also to perform
comprehensive assessments of the impact of glucose control regimens on health and QoL
(Anderson, Fitzgerald, Wisdom, Davis & Hiss, 1997).

Part Three – About the Study

Problem Definition
In the case of chronic illnesses like diabetes, it takes time before the benefits of
the treatment become apparent. Researchers have attempted to ascertain the relationship
between glycemic control and QoL in patients with diabetes using different measures,
either generic or diabetes-specific, or both. Two major longitudinal epidemiological
studies that investigated the benefits of metabolic control in managing reported no
differences in QoL between patients undergoing conventional treatment versus intensive
treatment aimed at achieving better glycemic control (The DCCT Research Group, 1996;
UKPDS Group, 1999). Correlational studies have found relationships between A1C and
well being and QoL (Van der Does et al., 1996; Nerenz, Repasky, Whitehouse &
Kahkonen, 1992; Guttmann-Bauman, Strugger, Flaherty, & McEvoy, 1998; Polonsky,
Anderson and Lohrer, 1995). Some other studies report no such association (Weinberger
et al.,, 1994; Lloyd, Sawyer and Hopkinson, 2001).
In designing new research to assess the relation between glycemic control and
QoL, it is useful to examine the QoL instruments used in these studies. The DCCT group
used a diabetes-specific instrument called DQoL, among others and the UKPDS group
used a generic instrument called the EQ5D. The possibility that the QoL instruments used
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in these studies lacked sensitivity to detect QoL differences between groups has not been
ruled out by the researchers of these studies (The DCCT Research Group, 1996; UKPDS
Group, 1999). Correlational studies reporting the relation between glycemic control and
QoL have used a range of generic measures (Weinberger et al., 1994; Lloyd, Sawyer and
Hopkinson, 2001; Nerenz, Repasky, Whitehouse & Kahkonen, 1992), diabetes-specific
measures (Guttmann-Bauman, Strugger, Flaherty, & McEvoy, 1998; Polonsky, Anderson
and Lohrer, 1995), while others have used measures describing physical and emotional
well being (Van der Does et al., 1996).
Hence, existing evidence is mixed on the nature of association between glycemic
control and QoL. Some researchers have expressed the need to distinguish between
measures of health status from those assessing QoL. Stating that health status measures
that broadly measure aspects of physical and mental functioning, and other specific body
functions and symptoms that are important in diabetes research, Bradley (1996) cautions
that they should not be confused with measures of the QoL of individuals.

Conceptual Framework of the Study
Overview
This study was conducted with the broad aim of performing an analysis of QoL of
patients with Type 2 diabetes receiving care at the West Virginia University (WVU)
Hospital outpatient primary care clinics. The study had a cross-sectional, descriptive
design. The specific objectives of the study were to assess the validity of the SF-12 and
the ADDQoL in the study population of Type 2 diabetes patients and to discuss the
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associations between QoL, demographic characteristics, and medical history of patients,
chiefly A1C levels.

Data and Measures
Patients with Type 2 diabetes at the WVU hospital outpatient clinics completed a
generic measure, the SF-12 and a diabetes-specific measure, the Audit of Diabetes
Dependent Quality of Life (ADDQoL). Other patient-reported data collected by mail out
questionnaire, included demographics, insulin use and diabetes duration.
Patient reported data was merged with a retrospective collection of patient clinical
and utilization data via patient’s electronic medical records. A comorbid disease score,
diabetes complications score, BMI and the number of ER & hospital visits in the past
were calculated from the retrospective data. A1C levels were directly abstracted from
electronic patient clinical records; both the most recent A1C value as well as the average
of A1C values in the past one-year were obtained.
The variables collected and analyzed in the study are categorized below:
QoL variables
•

The Audit of Diabetes Dependant Quality of Life (ADDQoL) score

•

Physical Component Score (PCS) score of the Medical Outcome Study Health
Survey 12-item Short Form (SF-12)

•

Mental Component Score (MCS) score of the SF-12
Demographic variables

•

Gender

•

Age
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•

Marital status

•

Ethnicity

•

Education

•

Type of health insurance
Medical history variables

•

Duration of diabetes

•

A1C (most recent A1C, and average value of A1Cs in the past year)

•

Body Mass Index (BMI)

•

Insulin use

•

Diabetes Complication Score

•

Charlson Comorbidity Index

•

Number of emergency room visits in the past 12 months.

•

Number of hospital admissions in the past 12 months.

Objectives of the Study
Objective A
This part of the study examines the dimensionality, internal consistency, and
construct validity of a the SF-12 and the ADDQoL in the study setting consisting of
patients with Type 2 diabetes, and report how they compare to the published findings
from other studies.
Objective B
One main objective of the study is to find out the relationship between a clinical
measure like A1C and a patient reported outcome like QoL. While a generic measure
12

indicates a general degree of health-related well being, diabetes-specific measures ask
patients to relate evaluations of well being to having and treating diabetes. Hence, this
question also examined differences in relationship between a generic and diabetesspecific measure, and A1C. The three categories of variables being studied are
demographic variables, clinical variables, and QoL variables. This question attempts to
determine the role of these variables, if any, in influencing generic and diabetes-specific
QoL.

Research Questions and Hypotheses
Research Questions for Objective A
One aim of the current study was to determine the reliability of the SF-12 and the
ADDQoL in the given study setting involving Type 2 diabetes patients. Additionally, the
study also tested the prevailing two-factor approach for the SF-12 and the single factor
approach for the ADDQoL. Construct validity of the instruments was also studied.

Research Questions for Objective B
In addition to assessing the psychometric properties of the ADDQoL and the SF12 in diabetes research, this study examines relationships between QoL and demographic
and clinical variables, including A1C levels. Specific research questions are mentioned
below:
Q1. Is there a relationship between between A1C and QoL (generic and disease-specific)
in Type 2 diabetes patients?
•

Hypothesis 1a - A1C level and ADDQoL score are not correlated

13

•

Hypothesis 1b - A1C level, and PCS and MCS scores of the SF-12 are not
correlated

•

Hypothesis 2 – There is no difference in the correlations between A1C level and
ADDQoL score, and A1C level and PCS & MCS scores of the SF-12.

Q2. What are the significant variables influencing generic QoL, measured by the SF-12
scores (PHC and MHC), and diabetes-specific QoL, measured by ADDQoL score, in
Type 2 diabetes patients?
•

Hypothesis 3 – A1C is a not a significant predictor of ADDQoL score.

•

Hypothesis 4 – A1C is a not a significant predictor of PCS score and MCS score.

Assumptions of the Study
This study depends on patients’ perspectives about the impact of diabetes on their
QoL. Indeed, this is the principle behind patient-reported outcomes. Any patient- reported
measure is influenced by biases. Hence, it is possible that in spite of a negative impact of
a disease on aspects of QoL, a patient may be unwilling to report that on a survey. The
study assumes that patients are capable of perceiving aspects of diabetes as it influences
their QoL, and also are willing to accurately report that on a survey.
The study uses the subjective appraisal of our primary contact physician at the
WVU Diabetes Institute in identifying Type 2 diabetes patients as potential participants.
It is assumed that these patients have been correctly identified, and that their medical
records also correctly identify their Type 2 diabetes status. In addition, the study uses
existing medical records to generate medical history variables for use in the study. It is
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assumed that patient information contained in these records has been coded appropriately
and is accurate.

Significance of the Study
The ADDQoL is a relatively new instrument providing a measure of
individualized QoL in patients with diabetes, and the SF-12 is increasingly being used
alongside other disease-specific measures. Although the reliability of the SF-12 has been
reported from its developmental work (Ware, Kosinski & Keller, 1996), there is little
research done on the reliability of the instrument among Type 2 diabetes patients. In one
recent study on the performance of the SF-12 in Type 2 diabetes patients, Johnson and
Maddigan (2004) reported that the PCS and MCS scores of the SF-12 were unable to
distinguish between groups of differing disease severity. However, data on psychometric
properties of SF-12 in this population was not provided in the study. The ADDQoL is a
relatively newer measure among diabetes-specific QoL measures. Apart from the
developer’s paper on the 20-item ADDQoL, no other published work discusses the
psychometric properties of the instrument. A one-factor solution for the ADDQoL has
been proposed (et al., 1999; Bradley & Speight, 2001), and the instrument has been stated
to be highly reliable, with reliability coefficient of 0.85 (Bradley et al., 1999).
This study benefits from recommendations of past research regarding the
complementary use of a generic and a disease-specific instrument in the assessment of
impact of the disease on patients’ QoL. This study will provide further information on
the reliability and construct validity of these two instruments when used in Type 2
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diabetes patients. Since there are currently no published studies that use both the
ADDQoL and the SF-12, this study will be the first to use the two QoL instruments.
As mentioned in an earlier section, researchers have used a variety of generic and
disease-specific measures, while some have used instruments measuring aspects of
physical and mental functioning and other specific body functions and symptoms. There
is no consensus on the relationship between A1C and QoL from these studies. In
analyzing the factors influencing QoL in diabetes, existing studies have examined
different types of variables, including demographics and medical history variables. While
patient report of comorbidities, complications, and medical resource may suffer from
recall bias, this study obtains such information from retrospective medical records,
eliminating threats to validity from this type of bias.
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CHAPTER TWO: LITERATURE REVIEW

Blood Glucose Monitoring and A1C levels

Checking blood glucose levels through regular blood glucose testing shows how
well diabetes is in control over a period of few hours. Another blood test that is
recommended for checking diabetes control over longer periods of time is an A1C (also
known as glycated hemoglobin) test. The test measures the amount of blood glucose
chemically attached to red blood cells; the higher the blood glucose, the greater the
percentage of glucose accumulated on the red blood cells. Hence, an A1C result reflects
the average blood glucose level for the previous 2-3 months, in comparison to blood
glucose testing which identifies control on a day-to-day basis. Not only can A1C allow
healthcare professionals to judge how well a patient’s diabetes treatment plan is working,
it can also assist in evaluating the long-term effects of diabetes management. Although
the A1C test is an important tool, it doesn’t really replace daily self-testing of blood
glucose as A1C tests don't provide day-to-day control information. The relationship of
average blood glucose and A1C results is depicted in Table 1.
The American Diabetes Association (ADA) recommends A1C testing when first
diagnosed with diabetes, and then at least two times a year if blood sugar is in the target
range and stable (ADA, 2001). In the case of patients taking insulin, or experiencing a
treatment change, or with very high blood sugar levels, an A1C test is recommended at
least every 3 months until blood sugar level improves (ADA, 2001). As illustrated in
Table 2, The ADA recommends that action be taken when A1C results are over 8%, and
considers the diabetes to be under control when the A1C result is less than 7%. One of
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the Healthy People 2010 objectives for WV is to increase the proportion of persons with
diabetes who have an A1C test at least once a year to 85% (WVDDHR, 2001).
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Table 1: Relationship of Average Blood Glucose and A1C Results*

A1C
% A1C

Corresponding Average Blood Glucose

Level of Control
Based on A1C level

mg/dl

14.0-10.1

Poor Control

360-240

10.0-9.1

Marginal Control

240-210

9.0-7.1

Good Control

210-150

7.0-5.0

Excellent Control

150-90

* obtained from Buckley & Goldstein, (1993)
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Table 2: Relationship of A1C to Average Whole Blood and Plasma Glucose Levels *
A1C

Mean Blood Glucose

Average Plasma

Interpretation

%

(mg/dL)

Glucose (mg/dL)

4

61

65

5

92

100

6

124

135

7

156

170

8

188

205

9

219

240

Action Suggested according to ADA

10

251

275

guidelines

11

283

310

12

314

345

Non-Diabetic Range

Target for Diabetes in Control

*obtained from Rohlfing and colleagues, (2002)
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Implications of the Diabetes Control and Complications Trial and Other Studies
The DCCT was a multi-center prospective controlled clinical trial that
demonstrated the beneficial effect of intensive diabetes treatment on reducing risk for
retinopathy, nephropathy, and neuropathy in subjects with Type 1 diabetes. Conducted
between 1983 and 1993, it was a randomized clinical trial designed to compare the
effects of intensive diabetes therapy with those of conventional diabetes therapy on the
development and/or progression of long-term complications of Type 1 diabetes.
Two groups of patients were followed long term: one treated conventionally with
a goal of clinical well being, and called the standard treatment group; and another treated
intensively with a goal of normalization of blood glucose, and called the intensive
treatment group. The goal of intensive therapy was to achieve glycemic control as close
to the non-diabetic range as possible, while minimizing hypoglycemia. While the
principal study endpoint was to study the development and progression of retinopathy,
other outcomes assessments included evaluations of renal, neurological, cardiovascular,
neuropsychological, and quality of life status.
The DCCT demonstrated the impact of glycemic control on the early
manifestations of microvascular complications. Results of the DCCT demonstrated that
intensive treatment led to strong reductions in the onset and progression of retinopathy,
nephropathy, and neuropathy (DCCT Research Group, 1993). The benefit of intensive
therapy resulted in a delay in the onset and a major slowing of the progression of these
three complications. These benefits were seen in all categories of patients irrespective of
age, sex, or duration of diabetes (DCCT Research Group, 1993).
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Patients with Type 2 diabetes were not studied in the DCCT. The UKPDS (United
Kingdom Prospective Diabetes Study) is one of the largest and longest studies performed
with Type 2 diabetes patients, and is another landmark diabetes study supporting the
value of glycemic control. The primary aim of the UKPDS was to determine whether an
intensive policy of improving blood glucose control with metformin, sulfonylureas or
insulin therapy protects patients from diabetic complications compared to a conventional
protocol that aims to improve blood glucose control through diet alone (UKPDS Group,
1998). The study results showed fewer incidences of diabetes-related complications like
retinopathy, nephropathy, and possibly neuropathy by lowering blood glucose levels in
Type 2 diabetes with intensive therapy described above (UKPDS Group, 1998). Thus, the
UKPDS results confirmed the results of the DCCT about the role of controlled glucose
levels in preventing diabetes-related complications.
Other large epidemiological studies have been planned since the DCCT and
UKPDS. One of them is the Wisconsin Epidemiologic Study of Diabetic Retinopathy
(WESDR), which examined diabetes patients to determine the prevalence and severity of
diabetic retinopathy and associated risk variables. The study found that the severity of
retinopathy was related to high A1C levels, among other conditions (Klein, Klein, Moss,
Davis and DeMets, 1984). A collaborative study between the DCCT and the WESDR
compared the DCCT cohort to a population-based Type 1 diabetes cohort from the
WESDR. The study concluded that the validity of generalizing the DCCT results to
patients with Type 1 diabetes in the general population was supported by the similar rates
of progression of retinopathy in conventionally treated patients, and the similar
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associations between the A1C levels and progression of retinopathy in the DCCT and
WESDR cohorts (DCCT Research Group, Klein & Moss, 1995).
Another study, the Epidemiology of Diabetes Interventions and Complications
(EDIC), can be described as a long-term follow-up of the DCCT cohort. The DCCT
cohort has been reported to be very stable ten years after the closeout of the DCCT, with
96% enrolled in the EDIC study (EDIC Research Group, 1999). The EDIC study aims to
achieve some scientific gains of conducting extended observational follow-up of subjects
from completed randomized controlled trials. Some of the benefits are additional
information on long-term effects, sub groups with different treatments and latest natural
history data (EDIC Research Group, 1999). With comprehensive data characterized at
baseline, the study group intends to examine hypotheses related to progression of
cardiovascular disease, nephropathy, neuropathy, and retinopathy.

Quality of Life Assessments in Patients with Diabetes
Type 1 and Type 2 diabetes are chronic illnesses that can influence QoL because
the treatments are burdensome and the complications can be debilitating and/or lifethreatening. For patients with diabetes, the disease and the demands of its day-to-day
management can be very challenging. Patients have to deal with their diabetes almost
every instant of their life and have to make continuous decisions that interfere with living
a normal life. The management of diabetes itself imposes considerable demands on
patients and their families, and affects patients both physically and psychologically.
Patients with diabetes may feel overwhelmed by the management of the disease. Apart
from the emotional and social burdens this may cause, they face the acute physical
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distresses of hypoglycemia or hyperglycemia and chronic physical distress of diabetesrelated complications (Rubin, 2000).
Polonsky (2000) has deliberated on the specific impact of diabetes on physical,
psychological and social functioning as follows:
Impact of diabetes on physical functioning
Diabetes can negatively affect physical well-being in three major ways. The most
important factor is the development of long-term complications like vision loss, kidney
damage, peripheral neuropathy resulting in chronic pain, amputation, and/or difficulty
walking. Other complications include sexual dysfunction, autonomic neuropathy
problems, and acute conditions like ketoacidosis. The Pittsburgh Epidemiology of
Diabetes Complications Study showed that patients with macrovascular disease or
nephropathy reported significantly poorer QoL compared with those who were free from
all complications, and that QoL significantly deteriorated according to the presence of
multiple complications (Lloyd, Matthews, Wing and Orchard, 1992). The second factor is
short-term complications and physical symptoms. Elevated blood glucose levels may lead
to increased fatigue, sleep problems, and other associated problems. Tight glycemic
control may lead to unwanted weight gain, hypoglycemia, and/or loss of hypoglycemic
warning signs. The third major factor is the lifestyle changes resulting from the demands
of the diabetes regimen. Polonsky (2000) suggests that to assess the impact of diabetes on
physical functioning most effectively, evaluation should focus on a patient's perceived
distress due to diabetes-specific symptoms as well as the perceived loss of physical
function, interference with common activities and loss of independence due to diabetes.
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Impact of diabetes on psychological functioning
Diabetes care can have a short-term and long-term impact on mood of patients.
Frustration can emerge out of the fact that the disease may not seem to respond in spite of
sincere efforts by patients. Cycles of elevated blood glucose levels and hypoglycemic
episodes can be exhausting, and can worsen already dampened spirits. Depression is not
generally listed as a complication of diabetes, but is widely prevalent in patients with
diabetes. Lloyd and colleagues (1992) reported greater depressive symptoms in patients
with macrovascular disease; greater number of complications were found related to
higher depression symptom scores. There is some suggestion that the stress of depression
may lead to neglect of diabetes care. Polonsky (2000) suggests that to assess this
dimension, evaluation should focus on a patient’s perceived emotional distress due to
diabetes-related symptoms, self-care, and broader diabetes issues.

Impact of diabetes on social functioning
The management of diabetes itself poses many challenges to a patient, as this may
necessitate changes in daily habits in order to manage the illness most effectively. For
instance, some patients are embarrassed to check their blood glucose or inject insulin in
front of others. For some, the requirement of meal planning may affect food choices at
social events that may be different from family/friend preferences. Thus, a patient with
diabetes may not receive all the cooperation from family and friends in social settings, be
it home or outside of home. Polonsky (2000) suggests that to assess this dimension,
evaluation should focus on a patient's perceived emotional distress due to diabetes-related
social situations.
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Thus, diabetes has major psychosocial implications and it influences selfmanagement behavior in terms of diminished self-care, leading to worsened glycemic
control in the long run. In this context, QoL assessments can play a role in predicting an
individual’s capacity to manage his or her disease and stay healthy in the long run
(Rubin, 2000). Satisfactory diabetes control can be achieved when this interdependence
between physical and psychological well being is addressed (Eiser & Tooke, 1993).
The changing dynamics of the health care system have influenced how diabetes
treatment is evaluated. With the emergence of managed care as a dominant influence on
health care delivery, there is an increasing emphasis on assessing the costs associated
with new and existing therapies and interventions. Health care planners are focusing on
short-term patient outcome measures like QoL and functional health status and
satisfaction with care. Patient assessed measures of health outcome are increasingly being
used alongside traditional biomedical measures for the evaluation of treatment and
management of diabetes (Garratt, Fitzpatrick & Schmidt, 2002).

Influence of Diabetes Treatment on Quality of Life
As described earlier, diabetes and its complications can adversely influence QoL.
In today’s clinical practice, achieving better glycemic control is a therapeutic goal for
both Type 1 and Type 2 diabetes patients. While the DCCT demonstrated that better
glycemic control can decrease the prevalence of complications in patients with Type 1
diabetes, the UKPDS proved that these results were applicable to patients with Type 2
diabetes as well (UKPDS Group, 1999). Diabetes treatments focus on achieving better
glycemic control, but these treatments itself can impose a burden on the patient and affect
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QoL (Rubin, 2000). Clinicians are becoming increasingly aware that maximizing their
patients’ QoL is an important measure of the effectiveness of health care (Weinberger et
al., 1994).
Anderson and colleagues (1997) suggest not limiting the goals of diabetes care
only to strict glycemic control, but also performing comprehensive assessments of the
impact of glucose control regimens on health and QoL. Testa (2000) lists the following as
areas on which the QoL literature on diabetes treatment has focused:
•

The state of health of individuals with serious health complications associated
with diabetes like renal failure, foot damage, blindness, and others

•

Psychological considerations of impact of diabetes and treatment regimen

•

Impact of newer dosage delivery systems, classes of drugs and treatment regimen.
Research may be able to determine whether lifestyle changes required to improve

glycemic control like and self-care behaviors (medication adherence, dietary restrictions,
glucose self-monitoring, exercise, and others) adversely influence QoL or not. If such
changes are not seen to be negatively influencing QoL, then this may be viewed
positively by physicians who are concerned that a particular treatment may produce the
required clinical benefits at the risk of compromising patients’ QoL (et al., 1994).
Alternatively, patients may find treatments intrusive in the immediate future and report
adverse influence on QoL. If such patients perceive improvements in QoL in the future in
the form of prevention of long-term complications, they may adhere to regimens and
report no effect of intrusive regimens on their QoL (Weinberger et al., 1994).
In keeping with the observations of major studies like the DCCT and UKPDS on
the relation between glycemic control and complications, it can be expected that better
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glycemic control may be associated with better QoL. Some researchers assume that QoL
at the start of treatment influences metabolic control and vice versa; some studies report
associations only in sub-populations of populations. In one such attempt, Weinberger and
colleagues (1994) discussed the following possible relationships between glycemic
control and QoL that could exist in patient populations seeking treatment for their
diabetes:
1) With fewer hyperglycemic episodes and decreased rate of complications, patients with
good glycemic control might report better quality of life.
2) With an added burden of complex regimens, along with more hypoglycemic
symptoms, patients with good glycemic control might report negative impact on quality
of life.
3) Patients with very good or very poor glycemic control may report relatively worse
quality of life.
Thus, it is possible to think of several different ways in which QoL and glycemic control
are related.

Generic and Disease-Specific Instruments to Assess QoL

Two broad categories of health-related QoL instruments have emerged – generic
or global, and disease-specific measures. Generic QoL scales are designed to be used
with any population regardless of the specific disease. Since they allow comparison
across disease categories and illness groups, broad-based policy decisions can be made
from generic QoL data (Anderson et al., 1997). However, the domains contained in
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generic measures may have little or no relevance to a specific patient group or disease
entity in which they are intended to be used. Generic measures may also lack items or
domains that are necessary to gain complete understanding of patients’ QoL in that
disease state. Generic measures offer the benefit of being applicable across disease
categories, but this can be a disadvantage when specific disease categories and research
questions particular to those diseases are being studied.
Rubin and Peyrot (1999) suggest that even a well-designed generic QoL scale
may not be able to address some aspects of living with diabetes that strongly affect QoL,
such as hypoglycemia, insulin injections, self-monitoring of blood glucose, and dietary
restrictions. Rubin and Peyrot (1999) also state that generic measures may not be specific
enough to detect effects in some areas of functioning, like the fear of diabetes-related
complications that may influence mental health. The Medical Outcomes Study (MOS),
which evaluated a generic measure of QoL, did not distinguish between the types of
diabetes under study and did not examine the effects of complications or type of
treatment (Jacobson, De Groot and Samson, 1994). Snoek (2000) has compiled a list of
domains relevant to diabetes QoL: symptom distress, general physical functioning,
mental/emotional state, social functioning, perceived burden of treatment regimen,
treatment satisfaction, and an overall sense of well-being.
Jacobson, De Groot and Samson (1994) also provide suggestions for assessing
QoL with multiple instruments that measure generic and illness-specific issues. If the
primary goal is to compare the results of a particular study with those conducted on
different illness populations, generic measures are valuable. If the purpose of QoL
assessment is to study disease-specific problems, disease-specific instruments should be
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used. Since each measure may offer different information, it may be useful to incorporate
both (Jacobson, De Groot and Samson, 1994).
In order to identify the factors most relevant to the QoL of people with a specific
disease, disease-specific measures are being added to generic measures (Rubin& Peyrot,
1999). However, Kaplan (1990) argues that biological variables are important only to the
extent that they are associated with key patient behaviors and long-term outcomes such as
physical and social functioning, hospitalization, and mortality.

Generic Quality of Life Measures
The Medical Outcomes Study Short-Form General Health Survey
One of the most widely used generic measures of QoL in studies of people with
diabetes is the Medical Outcomes Study (MOS) Short-Form General Health Survey, or
known as SF in short. The SF series numbers indicate the number of items that each SF
health questionnaire contains. The instrument originally developed, the SF-36, consists of
36 questions covering eight dimensions of health status (Ware and Sherbourne, 1992).
Shorter versions of the SF-36 have been developed. Ware, Kosinski, and Keller (1994)
generated two summary scores from the SF-36: The Physical Component Summary
Score (PCS) and the Mental Component Summary Scales Score (MCS). Ware, Kosinski,
and Keller (1995) later developed the SF-12, a subset of 12 items of the SF-36. Different
versions of the MOS Health Survey, commonly the SF-36, the SF-12, and the SF-8
(collectively referred to as the SF series), have been used in patients with a wide variety
of illnesses and backgrounds.
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The developers of the SF series recommend that the instrument be used to assess
outcomes of interventions, since the instrument is very sensitive to change. Generic
measures like the SF series are most useful for comparing QoL in people with different
diseases or the QoL in people who have no diseases with the QoL in people who have a
disease (Rubin & Peyrot, 1999). One study reported tight glycemic control to be
associated with lower ratings on the various SF-36 scales (Nerenz, Repasky, Whitehouse
& Kahkonen, 1992). The SF-36 has been validated among people with Type 2 diabetes in
general practice, with the finding that SF-36 scores were strongly affected by nondiabetic comorbidity (Woodcock, Julious, Kinmoth, and Campbell, 2001).
Other measures reported in the literature to assess general QoL in diabetes
patients include:
World Health Organization Quality of Life Assessment (WHOQOL-100)
(WHOQOL Group, 1998),
World Health Organization Quality of Life Assessment – Abbreviated Version
(WHOQOL-BREF) (WHOQOL Group, 1998),
Duke Health Profile (Parkerson, et al., 1981),
The Nottingham Health Profile (Hunt, McEwen & McKenna, 1981),
The Sickness Impact Profile (Bergner, Bobbitt, Carter, & Gilson, 1981), and
The Rand Quality of Well-Being Self-Administered survey (QWB-SA)
(Anderson, Kaplan, Berry, Bush, & Rumbaut, 1989).
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Disease-Specific Quality of Life Measures
Disease-specific scales focus on specific problems posed by a particular illness
and reflect particular limitations or restrictions associated with specific disease states.
They can include aspects of health considered by patients or clinicians to be of greatest
importance. The targeted focus of disease-specific instruments has the potential to make
them more responsive to changes in health. At this time, there are several measures that
attempt to evaluate the many aspects of diabetes-specific QoL as defined earlier. Some of
the different diabetes-specific QoL instruments are described below:

The Diabetes Quality of Life Measure (DQOL)
The DQOL is one of the more widely used instruments in the assessment of
diabetes related QoL. The instrument was developed for use in the DCCT, in patients
with Type 1 diabetes. Since the DCCT compared QoL of patients in intensive versus
conventional therapy, it was felt that the demands imposed by the two types of treatment
would lead to different levels of patient burden. The DQoL was hence developed to
assess patients’ perceptions of impact and satisfaction with specific features of diabetes
management. It has 46 items covering five dimensions: treatment satisfaction, treatment
impact, worries about long-term complications, worries about social and vocational
issues, and overall well being. Response to the items is on a 5-point Likert scale
(Jacobson, Barofsky, Cleary and Rand, 1998). A 15-item DQOL Brief Clinical Inventory
has been recently developed and tested (Burroughs, Desikan, Waterman, Gilin & McGill,
2004). Only in Type 1 diabetes patients were both self-reported diabetes care behaviors
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and satisfaction with diabetes control predicted as effectively as the full version of the
instrument.
In a review of health outcome measures for diabetes Garratt and colleagues
(2002) state that this instrument has good evidence for reliability, and internal and
external construct validity. The DQOL has been tested and validated in patients with
Type 2 diabetes (Jacobson, De Groot and Samson, 1994). Others are of the view that the
DQoL was designed specifically for Type 1 diabetics with intensive insulin treatment,
and may have deficiencies with assessing the quality of life for persons with Type 2
diabetes (Mannucci, Ricca, Bardini & Rotella, 1996). Jacobson, De Groot and Samson
(1994) showed that the DQOL compared favorably to the SF-36, although the SF-36 was
seen to be less sensitive to lifestyle issues such as diet or treatment.

The Audit of Diabetes-Dependent Quality of Life (ADDQoL)
The ADDQoL is an 20-item instrument that presents a comprehensive list of 18
life domains that diabetes might affect. It is applicable in both Type 1 and Type 2
diabetes (Bradley, Todd, Gorton, Symonds, Martin, and Plowright, 1999). Patients are
asked to indicate, on a 7- point Likert scale, the degree to which each particular domain
might be different "if I did not have diabetes". The respondent is allowed to indicate if an
item is not applicable to them and should be dropped from consideration (et al., 1999).
Having only 20 items, the measure does not require a great deal of time to administer.
Garratt and colleagues (2002) state that this instrument has good evidence for reliability,
and internal and external construct validity. Internal reliability as measured by
Cronbach’s alpha (0.85) is very good for this instrument (Bradley et al., 1999).
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Woodcock and colleagues (2001), who used the ADDQoL in conjunction with the SF-36,
found that the SF-36 was strongly affected by non-diabetic comorbidity in patients with
Type2 diabetes, supporting the complementary use of a diabetes-specific measure.

Diabetes Care Profile (DCP)
The DCP is a self-administered questionnaire that assesses the social and
psychological factors related to diabetes and its treatment. The instrument contains 234
items and sixteen scales. These scales assess the patient’s diabetes attitudes, diabetes
beliefs, self-reported diabetes self-care, and difficulties with diabetes self-care. The DCP
also contains questions concerning demographic information and self-care practices
(Fitzgerald et al., 1996). With 234 questions and taking 30-40 minutes to complete, it is a
long survey tool. Anderson and colleagues (1997) compared the DCP with the SF-36 and
found good correlation between the two measures and the number of complications for
patients who have Type 2 diabetes. The DCP has been reported as having predictive
validity regarding glycemic control (Fitzgerald et al., 1996).

The Appraisal of Diabetes Scale (ADS)
The ADS aims to assess how a person with diabetes evaluates the disease and its
impact. Instrument content is based on theory and previous research. The seven items use
a five-point scale and measure control, uncertainty, coping, affect of diabetes on life
goals, predictive view of diabetes and the degree of distress caused by diabetes. Carey
and colleagues (1991) state that the ADS can be useful as a quick (five minute) screening
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tool to assess a patient’s adjustment to diabetes or risk for noncompliance with a care
regimen. Garratt and colleagues (2002) state that this instrument shows good reliability,
validity, and test-retest analysis results. But the content validity of the instrument is
questionable since it was developed without patient input.

The Well-Being Enquiry for Diabetics (WED)
The Well-Being Enquiry for Diabetics (WED) is a measure of disease-related
quality of life intended for application in different clinical settings. The 50 items use a
five-point scale and measure four dimensions: symptoms, discomfort, serenity and
impact. These subscales were derived from an a priori categorization rather than from a
statistical analysis. The questionnaire has been validated in both Type 1 and Type 2
diabetes patients (Mannucci et al., 1996).
Other diabetes-specific QoL measures reported in the literature are listed below:
The Diabetes Impact Measurement Scale (DIMS) (Hammond & Aoki 1992),
The Diabetes-Specific Quality of Life Scale (DSQOLS) (Bott, Muhlhauser, Overmann &
Berger, 1998),
The Diabetes Health Profile (Meadows et al., 1996; Meadows, Abrams & Sandbaek,
2000),
The Problem Areas in Diabetes Scale (PAID-1) (Polonsky et al., 1995),
The ATT-39 (Dunn, Smartt, Beeney & Turtle,1986),
The Type 2 Diabetes Symptom Checklist (Grootenhuis, Snoek, Heine & Bouter, 1994),
and
The Diabetes -39 (D-39) (Boyer & Earp, 1997).
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Psychometric Properties of QoL Measures Used in the Study

The Medical Outcomes Study Short Form SF-12
The SF-36, as a generic QoL measure, has gained popularity as a measure of
outcome in a wide variety of patient groups and social surveys. The questionnaire
contains 36 questions covering eight dimensions of health status, shown in Table 3.
In addition to those above domains, the instrument has one self-reported health transition
item. In an effort to reduce the SF-36 from an eight-scale profile described above without
major loss of information, Ware, Kosinski, and Keller (1994) used data from the Medical
Outcomes Study to generate two summary scores from the SF-36: The Physical
Component Summary Score (PCS) and the Mental Component Summary Scales Score
(MCS). Consequently, Ware, Kosinski, and Keller (1996) suggested a subset of 12 items
obtained from the SF-36 and christened the instrument as the ‘SF-12’. The SF-12 has 12
items in common with the SF-36, covering eight domains as displayed in Table 4.

Rationale for Choosing the SF-12: A Comparison of the SF-12 and the SF-36
Although the SF-36 has proved to be a versatile instrument to assess general QoL,
it is considered long for inclusion in some large-scale health measurement and
monitoring efforts (Ware, Kosinski and Keller, 1996). Shorter measures can reduce the
respondent burden, but in doing so, it is important to balance the number of questionnaire
items against other important considerations like comprehensiveness of content and the
statistical precision of the scores (Ware, Kosinski, and Keller, 1996).
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The SF-12 was able to produce the two summary scales developed from the
original SF-36 with considerable accuracy, yet with far less respondent burden. PCS and
MCS scores calculated from the SF-36 and the SF-12 were almost identical. When
regression methods were used to select and score 12 items of the SF-36, the 12 items
predicted more than 90% of the variance in the PCS and MCS scores of the original SF36 (Ware, Kosinski, and Keller, 1996). Test-retest correlations of 0.89 and 0.76 were
observed for the 12-item PCS and MCS respectively. Correlations between SF-12 and
SF-36 versions of the PCS and MCS were 0.951 and 0.969 respectively, while the testretest reliability were 0.890 and 0.760 respectively (Ware, Kosinski, and Keller, 1996).
In another study, it was found that the level of change detected by the summary
scores of the SF-12 was the same as gained from the longer form instrument (Jenkinson
et al., 1997). Average scores for the two summary measures in the SF-12 closely
mirrored those for the SF-36. The summary scores may make trial and other longitudinal
data sets more easily interpretable due to the reduction of the number of statistical
comparisons from eight to two (Ware, Kosinski and Bayliss, 1995). Thus, the validity,
practicality and suitability of the SF-12 as a shorter form measure for the assessment of
the summary scales in longitudinal studies was demonstrated. Studies have indicated
favorable psychometric properties including the internal consistency and construct
validity of the SF-12 subscales. Jenkinson and colleagues (1997) caution that the
summary scores gained from the SF-12 are not identical to those gained from the SF-36.
However, this difference is small and the developers of the original instrument have
stated that such small differences are not meaningful either subjectively or clinically
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(Ware, Snow, Kosinski, and Gandek, 1993). Ware, Kosinski, and Keller (1996), however
recommend not producing an eight-scale summary from the SF-12.
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Table 3: Domains of the Medical Outcomes Study Short Form SF-36

SF-36 Domain

Number of items representing the domain

Physical functioning

10

Social functioning (2 items)

2

Pain (2 items)

2

General health perception (5 items)

5

Mental health (5 items)

5

Energy/vitality (4 items)

4

Role limitations due to emotional problems (3 items)

3

Role limitations due to physical problems (4 items)

4

39

Table 4: Domains of the Medical Outcomes Study Short Form SF-12

SF-12 Domain

Number of items representing the domain

Physical functioning

2

Social functioning (2 items)

1

Pain (2 items)

1

General health perception (5 items)

1

Mental health (5 items)

2

Energy/vitality (4 items)

1

Role limitations due to emotional problems (3 items)

2

Role limitations due to physical problems (4 items)

2
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The Audit of Diabetes-Dependent Quality of Life
Description
The Audit of Diabetes-Dependent Quality of Life (ADDQoL) is a 20-item scale
that presents a comprehensive list of 18 life domains that diabetes might affect for
patients with diabetes (Table 5). Two additional items report estimates of overall quality
of life, comparing life with and without diabetes.

Instrument Design
The design of the ADDQoL is influenced by the development of the Schedule for
the Evaluation of Individual Quality of Life (SEIQoL), an interview-based approach to
QoL measurement. The SEIQoL method involved asking the respondents to generate
domains of life that are important to them, evaluate how good or bad each aspect was
currently felt to be, and indicate the importance of each for their own QoL. Since
respondent-generated domains may be more feasible in face-to-face interviews, an
approach of providing domains was felt to be more practical, with an option of excluding
domains when not applicable. This approach was adapted to address diabetes-specific
issues and presented in a questionnaire format, resulting in the creation of the initial 13domain ADDQoL.
The ADDQoL attempts to evaluate diabetes-specific quality of life from an
attributional perspective (how diabetes may be perceived as interfering with well-being).
In contrast, the majority of the other scales assess QoL from an intrinsic perspective (how
the different aspects of diabetes may be perceived as burdensome). Rather than asking
about the degree to which problems associated with diabetes are occurring, this scale asks
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patients to imagine how life might be different without diabetes and compares it to their
current QoL with diabetes. This is a more complex task, one step removed from direct
questions about diabetes-specific quality of life (Polonsky, 2000). One advantage of this
approach is that it allows respondents to indicate how diabetes may be having a positive
effect in certain domains. Bradley and colleagues (1999) assert that none of the other
diabetes specific QoL measures allow the patient to indicate
1) which domains of life apply to them, and
2) the perceived importance of each domain for their QoL.
Respondents rate how diabetes impacts individual domains on a seven-point scale (the
impact rating), as well as how important the individual domains are to their QoL (the
importance rating), on a four-point scale. A ‘not applicable’ (N/A) option is provided for
domains that may not be applicable to a given individual. Impact ratings when multiplied
by the respective importance ratings yield scores ranging from –9 to 9 for each domain.
An average weighted impact score is derived by summing the weighted impact scores for
each domain and dividing the number of applicable domains. Thus, the patient's 18 scores
can then be arithmetically weighted, such that the total score is more strongly influenced
by those domains that a patient has selected as being most important.
The authors of the ADDQoL have given consideration to face or content validity
in instrument development. Patients and diabetes experts were involved in the generation
and confirmation of items.
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Table 5: Domains of the Audit of Diabetes Dependent Quality of Life

Item Number

Domain that the Item Represents

1

Working life

2

Family life

3

Social life

4

Sex life

5

Physical appearance

6

Physical activities

7

Holidays/ leisure

8

Travel

9

Confidence in ability

10

Motivation

11

Society reaction

12

Future

13

Finances

14

Dependence

15

Living conditions

16

Freedom to eat

17

Enjoyment of food

18

Freedom to drink
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Psychometric properties
In the developer’s published study on ADDQoL, Bradley and colleagues (1999)
have reported the following results for the 13-domain (15-item) ADDQoL:
•

Factor analysis revealed the existence of one factor when subjected to a forced
one-factor solution, suggesting that all items were associated together on this
single factor.

•

All the domain-specific ADDQoL items were relevant and important for a
substantial number of the respondents.

•

Insulin users reported significantly greater negative impact of diabetes on most
domains than those not using insulin.

•

People with complications of diabetes reported greater negative impact of
diabetes on their quality of life than people without complications. The mean
weighted average ADDQoL score correlated significantly with the number of
reported complications (Spearman r = -0.2141, p<0.005).

•

People reporting higher frequency of unacceptable hypoglycemia had greater QoL
impairment.

•

The diabetes specific ADDQoL score was predicted to be more sensitive to
change and responsive to subgroup differences than a generic instrument. The
rationale stated was that diabetes would have a greater reported impact on
diabetes specific domains of the ADDQoL such as enjoyment of food, worries
about the future and travel, than on standard QoL domains such as work, social
life, friends and family.
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Bradley and Speight (2002) in their DIABQoL+ study, have reported the following
results in the development paper for the 18-domain (20-item)ADDQoL:
•

As in the previous study, forced one-factor analysis revealed that all 18 items
loaded greater than 0.5 on one factor, indicating that the 18-item scale is highly
reliable.

•

The Diabetes Treatment Satisfaction Questionnaire (DTSQ), used along with the
ADDQoL in this study showed high satisfaction with treatment even as the
weighted ADDQoL scores were reported to be largely negative. Thus, the
instrument was able to report negative influence of diabetes on QoL even as
satisfaction with the treatment was found to be high.

Subsequent Studies
The DAFNE Study Group (2002) studied whether a course teaching flexible
intensive insulin treatment combining dietary freedom and insulin adjustment can
improve both glycemic control and QoL in patients with Type I diabetes. They used the
ADDQoL to measure QoL changes due to an educational program. A QoL difference was
not apparent after six months in the program, but became significantly improved after one
year (DAFNE Study Group 2002).

Reliability and validity of the ADDQoL
Reliability for the ADDQoL was assessed by Bradley and colleagues (1999),
revealing a Cronbach’s coefficient of 0.85. This, along with the results of the forced
one-factor factor analysis, provided support for combining the weighted items into a
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single ADDQoL score. As a measure of the construct validity of the measure, insulindependent subjects generally scored lower (=greater impact) on the ADDQoL than noninsulin-dependent subjects, and patients with diabetes complications reported
significantly greater negative impact of diabetes on QoL than did those without
complications (Bradley et al., 1999 and Bradley and Speight, 2002).

Rationale for choosing the ADDQoL
Wildes, Greisinger and O'Malley (2003) have performed a critical assessment of
twenty-four QoL measures for patients with diabetes. They have recommended the use of
the ADDQoL in diabetes QoL assessments, describing it as a brief and recent instrument
with good reliability and generated with patient input. Support for the psychometric
properties of the ADDQoL has been discussed earlier in this report.
In summarizing the properties of other well known diabetes-specific instruments,
Wildes, Greisinger and O’Malley (2003) describe the DQoL as having low to good
internal consistency reliability, and good test-retest reliability. They also note that the
DQoL is not a recent measure, is slightly long, and does not have strong evidence of
validity, in comparison to the other measures studied. In a review of health outcome
measures for diabetes, Garratt and colleagues (2002) state that this instrument has good
evidence for reliability, and internal and external construct validity. It is useful for both
insulin-dependent and non-insulin-dependent subjects. It allows the subject to judge the
relevance or importance of each item and to eliminate non-relevant or non-important
items from consideration before calculating the final weighted score.
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In summary, some of the considerations that went into the choice of the ADDQoL
as the diabetes-specific measure for the proposed study were its psychometric properties
(including good internal reliability, good face validity and construct validity), and low
respondent burden. The measure is designed for both Type 1 and Type 2 diabetes patients
although only Type 2 patients will be enrolled in the proposed study.

Rationale for the Combination of Instruments Used
The rationale behind the individual choice of the SF-12 and the ADDQoL has
been explained in earlier sections. Woodcock and colleagues (2001) validated the SF-36
among people with Type 2 diabetes in general practice, and made comparisons with the
ADDQoL. They reported that SF-36 dimension scores correlated best with relevant
diabetes-specific ADDQoL scores among respondents reporting no comorbidity. They
concluded that SF-36 scores are strongly affected by non-diabetic comorbidity in type 2
diabetes, supporting the complementary use of a diabetes-specific measure. They
suggested that sociodemographic and health variables be considered when comparing the
SF-36 scores with the ADDQoL scores.
While SF-36 scales have been found to be highly reliable given the extensive use
of this instrument, the ADDQoL is a relatively new measure providing a measure of
individualized QoL, and the SF-12 is increasingly being used alongside other diseasespecific measures. Published research has reported good reliability for these two
instruments, as described in an earlier section.
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A1C levels and Quality of Life

One of the traditional outcome focuses of most clinical investigations of diabetes
is glycemic control. Researchers are increasingly studying psychosocial variables
including QoL, utilizing various available measures along with measuring clinical
outcome variables. This added focus evolved with speculation that controlling glucose
levels might do more than prevent acute, life-threatening events. Since the DCCT
advocated more aggressive management of diabetes, there was need to address the
potential negative psychosocial effects of such intrusive treatment, while realizing the
importance of such measures and their role in therapy.
In an effort to examine the effect of intensive versus conventional diabetes
treatment on the emotional state of patients in greater depth, the DCCT group
incorporated multiple indices of QoL. They included a diabetes-specific measure called
Diabetes Quality of Life index (DQoL), the Symptom Checklist-90R (SCL-90R), the SF36, and a psychiatric event rate indicator, called intercurrent psychosocial events (The
DCCT Research Group, 1996). As mentioned earlier, the DQoL was developed for use in
the trial. The conclusion was that patients treated intensively with the goal of achieving
glycemic control as close to normal as possible did not face deterioration in QoL. One
reason proposed was that the increased stress associated with intensive diabetes
management may have been countered by a sense of well-being derived from improved
glycemic control. On the other hand, the measures used in the study may not have been
sufficiently sensitive to group differences to detect clinically meaningful changes in QoL.
Barring the DQoL, none of the measures used were diabetes-specific.

48

In contrast to the DCCT findings on the relationship between glycemic control
and QoL, a study on adolescent patients with Type 1 diabetes found significant
correlation between the total score on the DQoL and A1C levels, leading to the
conclusion that adolescents in better metabolic control reported better QoL (GuttmannBauman, Strugger, Flaherty, & McEvoy, 1998). Two types of A1C levels were employed
in the study: single A1C (value at the time of the study) as a measure of short-term
control, and mean A1C (in the year preceding the visit) as a measure of long-term
control. While both were correlated with quality of life, mean A1C level over a year
correlated more strongly with the DQoL assessment.
Several other studies have described cross-sectional relationships between
glycemic control and/or symptoms, and well-being or QoL in patients with Type 2
diabetes. As in patients with insulin-dependent diabetes, patients with Type 2 diabetes
also benefit from optimization of metabolic control by resultant reductions in risks of
long-term complications. Van der Does and colleagues (1996) concluded that higher A1C
levels were significantly associated with higher symptom scores, with worse mood, and
with worse general well being. Symptom scores were reported in the form of a
hyperglycemic score, a neuropathic score and a total score of the Type 2 Diabetes
Symptom Checklist (DSC-Type 2), while mood scores were reported using the Profile of
Mood States (POMS) and the Affect Balance Scale (ABS) was used to describe general
well-being. De Sonnaville and colleagues (1998) have assessed well being and symptoms
in Type 2 diabetes patients on insulin therapy. As with the results of the DCCT, insulin
therapy was found to improve glycemic control, but with little influence on the physical
and psychological well being dimensions studied.
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The UKPDS Group (1999) used two cross-sectional studies and one longitudinal
study of patients with Type 2 diabetes to determine the effects of therapies for improving
glycemic control on QoL. The first cross-sectional study used domain-specific
questionnaires including the Profile of Mood State, Cognitive Failures Questionnaire, and
other measures for symptoms and work satisfaction. The second cross-sectional study
used the EQ5D, a generic QoL questionnaire, while the longitudinal study used the
domain-specific questionnaires indicated above. The results showed that there were no
detectable differences in QoL between patients allocated to different therapies in the
UKPDS in the three sub-studies indicated above, leading to the conclusion that the
therapies could be given according to clinical requirements without concerns about the
negative impact on quality of life.
Weinberger and colleagues (1994) also studied the relationship between glycemic
control (represented by A1C levels) and QoL (using the SF-36) in patients with Type 2
diabetes in a Veteran’s Administration general medical clinic. Controlling for important
covariates defined a priori, no correlation was found between A1C levels and QoL, both
cross-sectionally, and longitudinally, over a period of one year. The researchers
suggested that this lack of association could explain the high non-compliance rates
among patients who were prescribed complex regimens. This lack of association may
have occurred due to the use of the SF-36, a QoL measure, or due to the nature of the
study population, with a high prevalence of diabetes-related complications skewing the
results. They concluded that it was important for patients to perceive a benefit from
following diabetes regimens in order to achieve good glycemic control, especially in
patients with a long duration of the disease.
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Reporting tight glycemic control to be associated with lower ratings on the
various SF-36, Nerenz and colleagues (1992) attributed this result to a complex
combination of demographic and medical variables rather than to the complexity of the
treatment regimen.

Evaluation of A1C Levels in Diabetes Management Programs
The impact of glycemic control on patient-reported outcomes such as QoL in
clinical trials has been discussed in the preceding section. In a similar manner, the impact
of chronic care clinics (or diabetes clinics, in this case), and diabetes management
interventions can be analyzed. In the assessment of effects of an intervention, it is useful
to use outcome measures like the patients’ QoL, in addition to physiological and
anatomical markers of disease progression. Assessment of QoL in an intervention should
focus on the patient’s illnesses and treatment experiences, by including patients’
satisfaction with treatment, and other domains influencing QoL (The DCCT Research
Group, 1996). This outcome is as important as glycemic control in comprehensively
evaluating new treatment approaches for patients with diabetes.
In an era of tighter health care budgets, reimbursement issues and financing
crises, a great deal of attention is being devoted to health and economic outcomes
assessments of new therapies and interventions. Quality of Life evaluation can make
important contributions to diabetes treatment effectiveness evaluations. Testa (2000) is of
the view that QoL can also help compare diabetes specialty care with non-specialty care
in terms of the overall health outcomes they produce.
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Glasgow and Osteen (1992) used published studies from Brown’s (1992) meta
analysis to state that studies performed in the setting of diabetes management programs
research have consistently reported on three outcomes: (1) Demographic characteristics
of the final participating sample, (2) changes in knowledge, and (3) A1C levels or mean
levels of blood glucose. In their observation, physiological outcomes that have most often
been measured are: A1C levels (53% of all studies), mean blood glucose levels (50%)
and, weight (59%).
Glasgow and Osteen (1992) conclude that published literature on diabetes
education program evaluations have focused too narrowly on assessing knowledge and
A1C outcomes to the exclusion of other important health outcomes like patient
functioning and QoL. They provide several suggestions about critically important
outcomes that either have been completely ignored in the evaluation of diabetes
education programs, or have been included very infrequently. These are:
•

Social and environmental context: impact of health insurance status and social
status;

•

Patient characteristics: demographic and medical variables of the target
population in addition to those of the final sample; rate of participation among the
eligible patients and characteristics of those electing versus those declining to
participate; attrition rates and characteristics of drop-outs versus those who
completed the program; and characteristics of patients who do well in the program
versus those who do not; and

•

Short-term health outcomes: patient functioning and quality of life assessments –
(only 1 out of the 59 published studies included in Brown’s (1992) meta analysis
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reported on QoL outcomes); coronary risk factor outcome measures like
cholesterol, blood pressure; smoking status; utilization measures like number of
diabetes-related emergency room visits and overnight hospital stays; and diabetes
complications.

Other Factors Influencing Quality of Life

In order to explain the factors that influence QoL in patients with diabetes,
researchers have used different kinds of variables. These include demographic
characteristics, clinical values, and indicators of health status.
Using the SF-36, Lloyd, Sawyer and Hopkinson (2001) reported the significant
impact of clinically diagnosed diabetes complication on QoL. Jacobson, De Groot and
Samson (1994) found that DQoL scores as well as the SF-36 scores were lower in
diabetes patients with greater severity of complications. In the same study, they reported
greater impact of diabetes on QoL due to insulin treatment in a population consisting of
patients with Type 1 and Type 2 diabetes. The DCCT Research group (1996) found no
impact of intensive treatment using insulin, on QoL represented by DQoL scores. Other
researchers have considered the type of treatment that diabetes patients were on,
including the use of oral medications, insulin, or simply diet and exercise (Glasgow,
1997; Jacobson, De Groot and Samson, 1994).
Similarly, the impact of cormorbid health status and past history of medical
conditions in patients with diabetes have been assessed for their impact on QoL (Van der
Does et al., 1996; Glasgow et al., 1997; Kerr, Smith, Kaplan and Hayward, 2003). Kerr
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and colleagues (2003) used an administrative database to determine the number of
outpatients visits and specific comorbid conditions, in order to account for the influence
of the health status of patients with diabetes on their QoL. Some of the other variables
considered by researchers include the number of previous hospitalizations (Glasgow et
al., 1997), BMI (Van der Does et al., 1996; Lloyd, Sawyer and Hopkinson, 2001) and
duration of diabetes (Van der Does et al., 1996; Glasgow et al., 1997).
The methodology employed in the study is discussed in the next chapter.
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CHAPTER THREE: STUDY METHODOLOGY

Study Setting

The West Virginia University Diabetes Institute (WVUDI) is a collaborative effort
to standardize outpatient diabetes education and care imparted by the department of
Family Medicine and the Physician Office Center’s Medical General Practice (MGP) and
Endocrinology clinics. While the department of Family Medicine sees patients of all ages
including children, the MGP and Endocrinology clinics provide care for patients older
than 18 years of age. At the time of designing the study in July 2004, Family Medicine
had an annual patient enrollment of around 11,500 (12, 263, as of Februrary 2005), with
approximately 18 physicians (not including residents) in the last 12 months, of which
1,100 patients had Type 1 or Type 2 diabetes. During the same period, MGP with 17
physicians had a patient enrolment of around 8,000, of which 3,300 had Type 1 or Type 2
diabetes.
The WVUDI plans to introduce a guidelines-based care program called Staged
Diabetes Management (SDM) in the WVU Hospital outpatient clinics. SDM was
developed by diabetes professionals at the International Diabetes Center (IDC), which is
based in Minneapolis, MN, USA. WVU researchers successfully competed for a
development grant from the IDC for conducting research on the effectiveness of the SDM
program. Prior to introduction of SDM, a baseline quality-of-care review is being
conducted in the process of meeting the grant obligations. For this purpose, patients with
Type 2 diabetes were being recruited by the WVU Hospital’s Office of Medical Staff

55

Affairs. On a separate group of patients, this study provided an assessment of the
relationship between QoL and clinical outcomes of these patients, prior to the
implementation of the SDM care algorithm.

Study Design

The study was a cross-sectional, descriptive study of QoL in persons with Type 2
diabetes at the WVU outpatient clinics. The study was observational in nature, in which
the variables of interest in the study, described earlier, were measured at a single time
period. QoL and demographic variables were measured using a self-report questionnaire
booklet (measures booklet), while the respective medical history data of the participants
were obtained from the hospital’s electronic medical records. These variables were
collected in order to examine the nature of associations between the QoL of patients
attending the clinics, and their medical history indicators, and demographic
characteristics.

Sampling Design and Patient Recruitment

As mentioned in a previous section, WVUDI has a combined diabetes patient
population of approximately 4, 400 patients had Type 1 or Type 2 diabetes in the three
different clinics. For the purpose of this study, an individual from the WVU Hospital’s
Office of Medical Staff Affairs (OMSA) served as a coordinator for identifying patients
with Type 2 diabetes from the WVU hospital’s medical records, while maintaining
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HIPAA compliance. There was a separate effort on the part of the OMSA to contact
around 250 patients with Type 2 diabetes for obtaining baseline information prior to the
introduction of SDM.
Since one of the major objectives of the present study was to assess the
relationship between A1C and QoL, it was necessary that A1Cs used in the study be done
within the past 90-120 days to provide a temporally associated reflection of their level of
glycemic control at the time of QoL assessment. The protocol of the present study did not
include taking a separate measurement of A1C for each participating patient but relied on
available medical records. Hence, an inclusion criterion was to only sample patients who
had an A1C performed anytime in the previous 90-120 days from the date of assessment
of QoL. With an anticipated date of commencement of mailing as the last week of
October 2004, it was decided to target the whole population of patients with Type 2
diabetes who had at least one A1C performed as of July 1, 2004. Records available from
the OMSA indicated 989 such patients.
At the time of designing the study, a decision had been made to obtain the support
of those physicians who patients met the study criteria, and have them endorse the study
in writing to their patients. Records were updated, to identify the physicians who were
currently responsible for the care of each patient among the target population of interest.
Once the population was identified, the clinic physicians providing care to these patients
were contacted and informed about the purpose of the research. A few of the physicians
had ceased working for WVUH, and in some cases, referrals of patients to other
physicians had been made. In all these cases, the names of physicians were updated and
the letters of endorsement were obtained, in which the physician’s signature was affixed
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to a personalized letter addressed to individual patients. Eleven physicians in the
department of Family Medicine, 14 from MGP, and three from Endocrinology signed the
letters, which were printed on OMSA letterhead. Three physicians did not participate and
their patients were excluded from the study. This brought the population of patients with
Type 2 diabetes available to be contacted, and who met the inclusion criteria, to 869.
The mailing commenced in the first week of November 2004. The following
items were included:
•

A personalized, signed cover letter from the patient’s specific physician,
explaining the purpose of the study and providing the contact information of the
research investigators of the current study, and the co-investigators at OMSA (see
Appendix A);

•

A measures booklet containing the SF-12, ADDQoL, and additional measures
used by other collaborating investigators (see Appendix B). The booklet also
included measures for data collected by other investigators on the protocol. These
other measures are beyond the scope of this study and will not be discussed; and

•

A postage-paid envelope addressed to OMSA.

Patients were given instructions to return the questionnaire packet to OMSA. Follow-up
reminder post cards were sent two weeks after the commencement of the mailing (see
Appendix C). Booklets were sent a second time to patients who responded to the
reminder cards and requested an additional copy. In order to reduce the burden on
volunteered time of a very busy OMSA staff, there were no additional follow-up
mailings. The co-investigators at OMSA coordinated the collection process of patient
responses with the clinical and medical history values to be used in the study.
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Data and Measures

The use of the various kinds of variables in explaining QoL of patients with
diabetes has been explaining in Chapter 2. In this study, three categories of variables
were collected: QoL, demographics, and medical history and disease severity.

QoL Variables
The impact of diabetes on QoL among the participating patients with Type 2
diabetes was evaluated using the SF-12 and the ADDQoL. The psychometric properties
of these measures, as well as the rationale for their inclusion in this study, have been
described in Chapter 2.

Scoring the ADDQoL
The ADDQoL consists of two overview items designed for audit purposes:
generic ‘present QoL’ and diabetes-specific ‘impact of diabetes on QoL’. The instrument
has an additional 18 items that concern the impact of diabetes on specific aspects of life,
of which three have a ‘not applicable’ (NA/) option [see Appendix A]. The instrument, in
the first step, requires respondents to rate the impact of diabetes on applicable domains
(part 'a' of an item) on a scale -3 (maximum negative impact) to +3 (maximum positive
impact). Domains with responses indicated as N/A were excluded from the scoring for
that individual. In the second step, respondents rate the importance of those domains for
their QoL (part 'b' of an item) on a scale 3 (very important) to 0 (not at all important). The
necessary steps to convert the responses obtained on the ADDQoL into QoL scores were
sent by the instrument’s developers at the time of obtaining the license to use it. The
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scoring algorithm is also summarized in the published work of the developers (Bradley,
Todd, Gorton, Symonds, Martin, and Plowright, 1999).
In the first step towards scoring the ADDQoL, responses recorded in the data set
were recalibrated to reflect the impact of diabetes on QoL, as depicted in Tables 6 and 7.
Impact ratings are multiplied by the corresponding importance rating to provide a
weighted-impact score for each domain from -9 (maximum negative impact) to +9
(maximum positive impact). Weighted impact scores are summed and divided by the
number of applicable domains, to give a final Average Weighted-Impact (AWI) score, as
summarized in Table 8. Thus, the ADDQoL scoring ignores non-applicable (N/A)
domains and gives greater emphasis to domains of greater importance to the individual.
The summary of scoring is shown in Table 8.
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Table 6: Format of the Two Overview Items of the ADDQoL Showing Scores Assigned
in Parentheses
I)

In general, my present quality of life is:
O

O

O

O

O

O

O

excellent

very good

good

neither good
nor bad

bad

very bad

extremely
bad

(3)

(2)

(1)

(0)

(-1)

(-2)

(-3)

II) If I did not have diabetes, my quality of life would be:
O

O

O

O

O

O

O

very
much
better

much
better

a little
better

the
same

a little
worse

much
worse

very
much
worse

(-3)

(-2)

(-1)

(0)

(1)

(2)

(3)
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Table 7: Format of the Domain-Specific Items of the ADDQoL Showing Scores
Assigned in Parentheses

1a) If I did not have diabetes, my working life and work-related
opportunities would be:
O

O

O

O

O

O

O

very
much
better

much
better

a little
better

the
same

a little
worse

much
worse

Very
much
worse
O

(-3)

(-2)

(-1)

(0)

(1)

(2)

(3)

1b) This aspect of my life is:
O

O

O

O

very
important

important

somewhat
important

not at all
important

(3)

(2)

(1)

(0)
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not
applicable

Table 8: Summary: Scoring Specific Domains in the ADDQoL

Weighted ratings

=

[unweighted rating (-3 to +3)] x ]importance rating (0 to 3)
for each domain]
Unimportant domains score 0, regardless of magnitude of effect
of diabetes. Domains unaffected by diabetes score 0, regardless
of their importance for QoL. Any non-applicable domains are
not scored.

ADDQoL score

=

Sum of weighted ratings of applicable domains
N of applicable domains

Scores vary from:

-9 (maximum negative impact of diabetes)

to:

+9 (maximum positive impact of diabetes)
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Since the ADDQoL includes a number of different life domains that may be
variously impacted by diabetes and of varying importance for overall QoL, missing data
were left as missing. Hence missing data for a domain would not contribute to the
weighted impact score for that domain, and this would be reflected in the number of
domains to be included to calculate the final AWI score. Since the instrument provides
the N/A option only for select life-domains, respondents may have chosen not to respond
to some other domains in part a) at all since there was no N/A option provided for them.
In such a case, imputing for missing data would have meant imputing a value for a
domain that a patient did not consider applicable to the impact of diabetes on his QoL.
Imputing in the above scenario may not have been a problem if the patient had indicated
in part b) that the domain was not at all important to his life, because the weighted impact
would eventually be zero. In the end, ADDQoL AWI scores could be calculated for 385
patients.

Scoring the SF-12
The necessary steps to convert the responses obtained on the SF-12 into QoL
scores were obtained from the SF-12 scoring manual (Ware, Kosinski, Bowker and
Gandek, 2002). The SF-12 consists of a subset of 12 items from the longer generic QoL
measure, the SF-36. Two of those items had a 3-point Likert scale, while the remaining
ten items had a 5-point Likert scale (See Appendix A). Recoding of some of the items
was needed for similar reasons as was done for the ADDQoL. In the case of the SF-12,
four such items were recoded such that a higher value indicated better heath on all SF-12
items.

64

As has been explained in a previous section, the 12 items of the SF-12 represent
eight domains. After item recoding, a raw score was computed for each domain. This raw
score is the simple algebraic sum of responses for all items in that domain, as shown in
Table 9.
The next step involves transforming each of the eight raw domain scores to a 0100 scale using the formula shown below:
Transformed scale =
[(Actual raw score-lowest possible raw score) / Possible raw score range] * 100
In the next step, the eight raw domain scores were standardized using a z-score
transformation using means and standard deviations (SD) of the respective SF-12
domains as obtained from a 1998 U.S. general population (See Table 10). A z-score for
each domain is computed by subtracting the 1998 general U.S. population mean from
each SF-12 domain score (on a 0-100 scale) and dividing the difference by the
corresponding domain SD (on a 0-100 scale) from the 1998 general U.S. population.
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Table 9: Calculating SF-12 Raw Domain Scores from the Recoded Items

SF-12 Domain

Contributing items

Lowest and highest
possible raw scores

Physical Functioning (PF)

Items 2a+2b

2,6

Role Physical (RP)

Items 3a+3b

2,10

Bodily Pain (BP)

Item 5

1,5

General Health (GH)

Item 1

1,5

Vitality (VT)

Item 6b

1,5

Social Functioning (SF)

Item 7

1,5

Role Emotional (RE)

Items 4a+4b

2,10

Mental Health (MH)

Items 6a+6c

2,10
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Table 10: Calculating SF-12 Standardized Domain Scores from Raw Domain Scores

SF-12 Domain Z score

Formula for Z-score

Physical Functioning Z-score (PF_Z)

PF_Z = (PF - 81.18122) / 29.10558

Role Physical Z-score (RP_Z)

RP_Z = (RP - 80.52856 ) / 27.13526

Bodily Pain Z-score (BP_Z)

BP_Z = (BP – 81.74014) / 24.53019

General Health Z-score (GH_Z)

GH_Z = (GH – 72.19795) / 23.19041

Vitality Z-score (VT_Z)

VT_Z = (VT – 55.59090) / 24.84380

Social Functioning Z-score (SF_Z)

SF_Z = (SF – 83.73973) / 24.75775

Role Emotional Z-score (RE_Z)

RE_Z = (RE – 86.41051) / 22.35543

Mental Health Z-score (MH_Z)

MH_Z = (MH – 70.18217) / 20.50597
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After z-scores were computed for each of the eight domains, aggregate scores for
the physical and mental health summary measures were calculated (See Table 11). In
doing so, each of the eight domains contributes to a different extent towards both
summary measures, depending on a physical factor score coefficient for the domain on
the summary measure.
In the final step, the aggregate physical and mental health summaries were
transformed to the norm-based (50, 10) scoring (NBS). This method entials performing
linear transformation of scores to achieve a mean of 50 and a SD of 10 in the general U.S.
population, for both the physical and mental health summary measures, as shown in
Table 12.
For the sake of consistency, missing data on the SF-12 were left as missing. All
the above procedures resulted in final PCS and MCS scores being obtained for 348
patients.
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Table 11: Calculating SF-12 Aggregate Physical and Mental Summary Scores from
SF-12 Standardized Domain Scores
SF-12 Aggregate summary score

Formula

Aggregate Physical

(PF_Z * 0.42402) + (RP_Z * 0.35119) + (BP_Z * 0.31754) +

Summary scores (AGG_PHYS)

(GH_Z * 0.24954) + (VT_Z * 0.02877) + (SF_Z * -0.00753) +
(RE_Z * - 0.19206) + (MH_Z * - 0.22069)

Aggregate Mental

(PF_Z * -0.22999) + (RP_Z * -0.12329) + (BP_Z * -0.09731) +

Summary Score (AGG_MENT)

(GH_Z * -0.01571) + (VT_Z * 0.23534) + (SF_Z * 0.26876) +
(RE_Z * 0.43407) + (MH_Z * 0.48581)
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Table 12: Calculating SF-12 Physical and Mental Summary Scores
SF-12 Aggregate summary score

Formula

Physical Component Summary (PCS)

= 50 + (Aggregate Physical Health Summary *10)

Mental Component Summary (MCS)

= 50 + (Aggregate Mental Health Summary *10)
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Demographic Variables
Demographic variables were obtained by patient self-report from the measures
booklet. These included the respondent’s age category, gender, education, race and health
insurance providers. These variables were re-categorized to run regression models. Age
was dichotomized as ‘equal to or less than 60 years of age’ and ‘more than 60 years of
age’. Marital status was dichotomized as being ‘married or with a partner’, or not
(‘single, divorced, separated or widowed’). Race was dichotomized as ‘white’ and ‘nonwhite’. Education was re-categorized as ‘up to high school’, ‘some college / vocational
course’, and ‘college degree and beyond’, while insurance was re-categorized as ‘no
insurance’, ‘state/federal insurance’, and ‘private insurance/managed care’.

Medical History Variables
Self-reported variables
Patients self-reported whether or not they use insulin, the type of treatment for
their diabetes (‘diet and exercise only’, ‘oral medications only’, ‘insulin only’, and ‘oral
medications and insulin’), and duration of diabetes (in years) in the measures booklet.

Variables collected from medical databases
A1C and BMI
The Diabetes Clinic Database can be described as a lab-value database consisting
of records of patients who consult physicians at the WVUDI clinics for the management
of their diabetes. The database includes A1Cs, lipid profile, blood pressure, and other
clinical information for each patient along with the dates when the respective lab values/
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information was obtained. At the time of most visits, nurses measure the blood pressure
of patients and weigh the patients. Other lab values like AIC, lipid profile and others are
ordered periodically per physician recommendation. These lab values, as well as
physician transcriptions notes, are also available on the electronic interface system called
Medsite. The OMSA, that coordinated the mailing on behalf of the study, also tracked the
patients who agreed to respond and participate, and made available the desired lab and
BMI values for all patients who participated. A1Cs were updated to include the most
recent values, considering the month of November 2004 as the period of QoL assessment,
and in keeping with the duration of applicability of an A1C reading as discussed earlier.
Missing height and weight information for a few patients were obtained from chart
reviews in order to calculate BMI.
Height (in feet) and weight (in pounds) information of respondents obtained from
chart review was used to calculate BMIs using the formula (CDC, n.d.):
BMI = [Weight in pounds / (height in inches)2 ] * 703

Hospital admissions and ER visits in the past year
Two databases were used to obtain diagnosis information for physician office
visits, emergency department visits, and hospitalizations for all patients participating in
the study. Treatment information was abstracted not just pertaining to the treatment of
their diabetes, but for all disease conditions that the patients had. The University Health
Associates (UHA) database derives its information from the IDX billing system, which is
a software package that tracks patient appointments and billings. After receiving care
from a provider, the patient receives a fee slip that is tracked by the IDX system within
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two days of the visit. In addition to the charges, the fee slip also consists of diagnosis
information that is later coded into ICD-9 format by the coding department. The WVU
Hospital database provides information on hospital and ER encounters. It tracks the bills
that patients receive upon discharge from the hospital, and among others, it contains ICD9 diagnosis codes associated with each hospital and ER visit. For purpose of the study,
the information used from these databases included ICD-9 codes for different types of
medical services utilization, and the number of ER visits and hospital admissions in the
twelve-moth period between December 1, 2003 to November 30, 2004.

Charlson Comorbidity Index
The Charlson co-morbidity index based on medical claims in the 12-month period
described above was used to measure co-morbidity. The Charlson Index consists of a list
of 19 medical conditions, with each condition being assigned a weight from one to six.
This weight was derived from relative risk estimates of proportional hazard regression
models using clinical data (Charlson, Pompei, Ales and MacKenzie, 1987). The Charlson
index for an individual is the sum of weights for all prevalent conditions (among the list
of 19 conditions) during a specified time period. There are a few indices that are
primarily based on the Charlson comorbidity index. The version by D’Hoore and
colleagues (1996), is one of the few Charlson indices for use with administrative claims
data and was used in this study. This version is based on only the first three digits of
ICD-9 codes. Diagnosis codes related to diabetes were excluded in the computation of
this index.
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Diabetes Complications Score
In addition to the Charlson co-morbidity index, a diabetes complications score
was computed. The complications score is a sum of the dummy variables that code for
the presence or absence of ICD 9 codes for four diabetes-related complications: renal,
ophthalmic, and neurological complications, and peripheral circulatory disorders. Thus,
the diabetes complications score can take values from zero to four.
A unique identification number, known only to the OMSA co-investigators, was
assigned to each participant across databases, while de-identifying the dataset. Every
patient in the database was identified by a unique identification number. The risk of
identifying patients was minimal due to the use of this delimited data set and due to
absence of any Protected Health Information (PHI).
In summary, the diabetes severity variables collected were A1C, insulin use status
and treatment type, duration of diabetes and the diabetes complication score. The
relationship between the QoL, medical history and disease severity, and demographic
variables was then assessed in order to answer the research hypotheses, as explained in
the next section.

74

Data Analyses

Objective A
In order to evaluate the factor structure of the ADDQoL and the SF-12, and perform
instrument reliability assessment, the following methods were used:
Two tests were initially conducted in order to assess the adequacy of the sample
for conducting factor analysis. In the Kaiser-Mayer-Olkin (KMO) measure of sampling
adequacy, high values (close to 1.0) generally indicate that a factor analysis may be
useful with the data. The second test for adequacy of the sample for factor analysis is the
Bartlett test of sphericity. Very small values (less than .05) indicate that there are
probably significant relationships among variables; this would indicate that the sample
does not produce an identity matrix and is adequate for factor analysis.
Both the ADDQoL and the SF-12 are QoL instruments with established factor
loadings derived from exploratory factor analyses performed by the respective
developers. The ADDQoL has a single-factor structure (Bradley, Todd, Gorton,
Symonds, Martin, and Plowright, 1999), and the SF-12 has been shown to have a twofactor structure ((Ware, Kosinski & Keller, 1996). Exploratory factor analysis attempts to
explain the number of factors that are required to explain the relations among a set of
indicators and with the estimation of factor loadings (Pedhazur, 1991). One of the major
purposes of confirmatory factor analysis is to test hypotheses regarding the number of
factors underlying the relations among a set of indicators, among others (Pedhazur,
1991). Hence, confirmatory factor analyses, using principal components method, were
conducted by specifying a priori, on the basis of previous research, the number of factors
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to be extracted. Varimax rotation was used within the principal components analysis. For
the ADDQoL, the eighteen items were used, while for the SF-12, the z-scores of the eight
subscales were used to perform the above-mentioned procedures. The following criteria
were used to make a decision on the prevailing dimensionality of the instruments: the
scree plot, the total percentage variance explained by the factors forced into the solution,
and the loading of items or subscales on the factors emerging from the rotated solution.
Once the factors were reduced, scales were analyzed for their reliability.
Indices of reliability give an indication of the extent to which the scores produced
by a particular measurement procedure are consistent and reproducible. A measurement
procedure is reliable to the extent that items within the same scale give the same results
or to the extent that an individual scores the same across repeated administrations of the
scale (Nunally and Bernstein, 1994). Of the methods available to estimate reliability, one
of the most frequently used and recognized is the internal consistency reliability method,
which examines the equivalence of responses within the same test from a single
administration (Nunally and Bernstein, 1994). Internal consistency reliability using
Cronbach’s alpha was used to estimate the reliability of the scales emerging from the
factor analytic procedure described above.
An instrument is said to be valid to the extent that it measures what it purports to
measure, and research data are said to be valid to the extent that the results of the
measurement process are accurate (Huck, 1996). A widely used classification used with
types of validity of measures is content, criterion, and construct. It was decided to assess
the construct validity of the instruments being used in the study, the ADDQoL and the
SF-12, since it was within the scope of the study. Construct validation is concerned with
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validity of inferences about unobserved variables (the constructs) on the basis of
observed variables (their presumed indicators) (Pedhazur, 1991). Three basic techniques
to discuss construct validity are logical analysis, internal-structure analysis, and crossstructure analysis (Pedhazur, 1991). In logical analysis, certain conceptual relationships
that are connected with the construct in question in some logical way are selected, and
correlational evidence is examined to determine strength of relationships between the
construct in question and other variables. Internal structure analysis involves performing
factor analysis. In cross-structure analysis, probable high and low scoring groups on an
instrument are identified on logical grounds a priori, and it is demonstrated that certain
groups obtain higher scores on an instrument than other groups. Construct validity of the
ADDQoL and the SF-12 was examined by investigating sub-group differences.

Objective B
In order to assess the bivariate relationship between A1C and QoL (generic and
diabetes- specific), the following methodology was employed: Spearman’s rank
correlation was used to calculate the significance of the direction and magnitude of
relationship between the uncategorized A1C value and the average weighted ADDQoL
score and PCS & MCS scores. For those respondents for whom both ADDQoL and PCS
& MCS scores were available, Hotelling’s t statistic was calculated to compare the
correlations between ADDQoL and A1C, and PCS& MCS scores and A1C. This is a ttest used to test for the significance of the difference between two dependent correlations
from the same sample.
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In order to identify the variables significantly influencing QoL (generic and
diabetes- specific), the following methodology was employed: Univariate analyses using
ANOVA were used to test the effect of individual variables on QoL. Multivariate
regression analyses were also used to control for the effect of covariates in order to test if
A1C is a significant predictor of generic QoL or diabetes-specific QoL. Three sets of
regression models were used, with ADDQoL average weighted scores as the dependent
variable in a model predicting diabetes-specific QoL, SF-PCS score as the dependent
variable in the second model and SF-MCS score as the dependent variable in the third
model. The effects of recent A1C and average A1C in the past year, on QoL were
independently assessed in separate models.
Sequential regression (also called hierarchical regression) models and statistical
regression (also called stepwise regression) models were built in order to explain the
relationship between QoL and the various predictors. In sequential regression, the order
of entry of variables is assigned by the researcher according to logical or theoretical
considerations (Tabachnick and Fidell, 2001). One point of view is to accord early entry
to variables of greater theoretical importance, or to those variables that are presumed (or
manipulated) to be causally prior, while the opposite view is to introduce the relatively
unimportant variables first, and test the added prediction obtained by the introduction of
the other variables in the model. Hierarchical regression is used in explanatory situations
when there is some basic knowledge on the relationships between at least some of the
variables being employed. In this study, covariates were entered sequentially into the
model the following order in groups in order to separate their effects from the effect of
the primary independent variable, A1C:
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Block 1: A1C, insulin use, complications score, duration of diabetes
Block 2: BMI, Charlson comorbidity score, number of hospital visits, number of ER visits
Block 3: Demographic variables: Age, gender, race, marital status, type of insurance.
In statistical regression, the order of entry of variables is not decided by the
researcher, but is based only on statistical criteria. In this technique, predictors are
automatically introduced into the model in the order that they contribute significantly to
the total model fit, with those predictors contributing most to total R2 entering first.
Statistical regression enables identification of a subset of independent variables (IV) that
can predict the dependent variables (DV) by eliminating those IVs that do not provide
added prediction to the IVs already in the model (Tabachnick and Fidell, 2001). Given
the nature of the technique, it is employed in exploratory research situations and for
purposes of prediction (Cohen, Cohen, West and Aiken, 2003). Hence the technique may
be used when a large pool of independent variables is available, but backed by little
theory to guide selection among them (Cohen, Cohen, West and Aiken, 2003). As
explained in an earlier section, there is no consistent relationship between generic and
diabetes-specific QoL in Type 2 diabetes patients and other predictors employed in the
study, as reported in literature. Hence the statistical regression technique was additionally
employed to identify those independent variables most significantly predicting QoL in
the current study data. Specifically, any variable was allowed to be introduced as a
predictor in the model if the significance level of its F value was less than the entry
criterion of 0.05, and was removed if the significance level was greater than the removal
criterion of 0.10. Correlation among predictors was checked before-hand (Tabachnick
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and Fidell, 2001) in order to prevent the loss of variables for consideration in the stepwise
regression procedure due to multicollinearity situations within the data.
SPSS 10.0 was used for all the analyses in the study.

Sample Size Calculations and Power

Power is the likelihood that a study will detect a true effect of a given magnitude
if it actually exists (a true positive). Power can also be broadly termed as the probability
that a statistical significance test will reject the null hypothesis for a specified value of an
alternative hypothesis. Hence, power of a study is also the probability of avoiding a beta
error, in which we fail to reject the null hypothesis which is false. It is important to
consider power in research designs because studies with low power analyses may be
inconclusive.
A priori power analyses are conducted in order to ascertain the sample size
required to perform the analyses necessary for a study at a level of power desired prior to
the start of the study. For this purpose, it is necessary to decide upon the alpha level (the
probability of making an alpha or Type 1 error) for the analysis, the desired power
(1 minus the probability of making a beta or Type 2 error), and the effect size. Effect size
can be conceived of as a measure of the distance between the null hypothesis and the
alternate hypothesis. Hence, effect size refers to the underlying population rather than a
specific sample. While specifying effect size in research that has clinical implication, it is
typical to decide the degree of deviation from the null hypothesis that is large enough to
be clinically relevant.
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In order to perform power calculations for the various analyses in the study, a
software package called G-Power (Faul & Erdfelder, 1992, and Erdfelder, Faul &
Buchner, 1996) was used.

Objective A
There is no consensus on the sample size required to perform factor analysis, and
methodologists differ in this regard. Certain rules of thumb include requiring at least 10
cases for each item in the instrument being used. Bryant and Yarnold (1995) recommend
that the subjects-to-variables ratio be no lower than 5.

Objective B
As explained in a previous section, evidence is mixed about the association
between A1C and QoL. While the magnitude of correlations calculated to test hypotheses
1a and 1b were used as the effect size (deviation from the null hypothesis), the alpha
level was decided as 0.05. Since a variety of QoL instruments have been used in
literature, there was no standard effect size to use while calculating the sample size
required in conducting the correlation analyses. Hence, a conservative medium effect size
(0.3) (Cohen, 1998) was chosen along with a required power of 0.8 to 0.9. This resulted
in a required sample size of 64 for a power of 0.8, and 111 for a power of 0.9.
The a priori calculation of required sample size necessitated making a decision on the
anticipated effects size index for regression, f2 (Cohen, 1988). f2 reflects the proportion of
variance accounted for by some source in the population (PVs) relative to the residual
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variance proportion (PVe), such that f2 = PVs / PVe. Using multiple regression with a set
of predictors, the hypothesis tested was that the correlation of a set of predictors with a
dependent variable is zero in the population. While f2 would be equal to R2 / 1-R2 (where
R2 is the coefficient of determination obtained from the regression using the set of
predictors), the required power was between 0.8 and 0.9, with an alpha level of 0.05. For
a set of predictors explaining 20% of the variance in the dependent variable, f2 would be
0.25, and with 14 predictors, a sample size of 86 is needed to achieve a power of 0.8 and
105 is needed to achieve a power of 0.9. For a set of predictors explaining 10% of the
variance in the dependent variable, f2 would be 0.11, and with 14 predictors, a sample
size of 179 is needed to achieve a power of 0.8 and 222 is needed to achieve a power of
0.9.
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CHAPTER FOUR: RESULTS

The previous chapter discussed the methodology employed, and data sources collection
procedures. The current chapter first provides a descriptive overview of the study results,
and then explains the results of each hypothesis indicated in Chapter one.

Overview of Results

The total number of responses received was 412. This study included only
patients with Type 2 diabetes, so it was decided to scrutinize the medical charts of those
respondents who reported using only insulin for the treatment of their diabetes to be sure
they were not Type 1 patients. Physicians increasingly prescribe insulin to patients with
Type 2 diabetes, but the need was felt to check if the respondents reporting insulin-only
treatment were indeed Type 2 diabetes patients. In addition, chart reviews were
performed for all respondents whose hospital records indicated only ICD-9 diagnoses
related to Type 1 diabetes. After careful review of all these medical records, and
consulting with our co-investigator physician at the OMSA, it was decided to drop 27
respondents from the study since they were resolved as patients with Type 1 diabetes. All
other patients were regarded as Type 2 diabetes patients; hence there were 385 usable
responses, leading to a usable response rate of 44.3%. All of these met the inclusion
criterion of having had at least one A1C measurement as of June 1, 2004; this study,
during its inception, was designed as a population study based on this criterion. For each
of the 385 respondents, the average of available A1C measurements in the past one year
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was also calculated. In order to provide a temporally appropriate assessment of the
relationship between a recent level of A1C and QoL, a subset of 360 respondents was
identified, for whom the latest A1C measurement was taken no more than 120 days prior
to the commencement of the study in November 2004. As explained earlier, this decision
was taken from prevailing knowledge, and in agreement with our physician coinvestigator’s observation that an A1C is a reflection of the average blood glucose level
over 90-120 days.

Descriptive Statistics for Total Sample Response Data

Overview of Descriptive Statistics
The demographic and diabetes/medical history variables and responses to the QoL
instruments were collected from the measures booklet. The information obtained from
chart reviews included A1C levels, BMI, lipid profile, and ICD-9 diagnoses (to calculate
the number of ER visits and hospitalizations in the previous year, the Charlson
comorbidity score, and the diabetes complications score).

Demographic Variables
The distribution of the respondents by the various demographic variables is
depicted in Table 13. Data on age was collected as a categorical variable, since the IRB
protocol did not allow for collection of actual respondent age. About 28% respondents
were in the age group of 50-59 years, while 26% respondents were in the age group of
60-69 years. Given this distribution, the variable for age in the dataset was dichotomized
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such that 47.4% of the sample was less than 60 years of age. Other demographic
variables were dichotomized wherever appropriate, as described in an earlier section.
Nearly 57% of respondents were female, and 94% respondents were white. About 63% of
respondents reported being married or with a partner while more than 37% were single,
divorced, or separated. Response regarding the highest level of education indicated that
about 53% of respondents completed high school or below. Only 7.5% of respondents
reported not having insurance; 67.5% reported having some kind of government
insurance as their primary insurance. It was possible to identify the clinics where patients
were receiving care for their diabetes at the time of sending questionnaires via survey
mail out. Forty percent of the respondents received care for their diabetes from the
Family Medicine clinics, 31.4% were from Endocrinology, while 28.6% were from MGP.

Medical History Variables
The mean self-reported duration of diabetes was 10.2 yrs (+ 9.1). Insulin use
status was also obtained from self-report, in the form of a yes/no question.
Approximately 42% of Type 2 respondents reported being on insulin. From the responses
to questions that were a part of another co-investigator’s research objectives, it was
possible to identify type of diabetes treatment of the respondents. While 50.3% of the
respondents reported that they were on oral medications alone, 31.7% were on both oral
medications and insulin, and 9.4% were on insulin alone.
Mean A1C (recent) for the respondents was 7.2 (+1.4) among the 360 respondents
for whom the value was available. A1C values were categorized into levels of glycemic
control, with 55% of the respondents in excellent glycemic control (A1C < 7.0), 33.9% in
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good glycemic control (A1C between 7.1 and 9.0), 7.8% in marginal glycemic control
(A1C between 9.1 and 10.0), and 3.3% in poor glycemic control (A1C above 10.1). The
mean of respondents’ average A1C over the previous year was 7.24 (+1.3) among the 384
respondents for whom the average A1C could be calculated. Paired samples t-test
revealed that there was no significant difference between respondents’ recent A1C value
and the average A1C value. Since almost 89% of respondents were in excellent to good
glycemic control (A1Cs equal to or below 9.0), it was decided to dichotomize the
respondents into two groups: one group that had A1Cs below 7.0 and the second group
that had A1Cs equal to or above 7.0. This classification was based on the ADA’s clinical
practice recommendation that providers should adjust management plans for their
patients in order to achieve an A1C goal of below 7.0 (ADA, 2005).
Height (in feet) and weight (in pounds) information of respondents obtained from
chart review was used to calculate BMIs using the formula (CDC, n.d.):
BMI = [Weight in pounds / (height in inches)2 ] * 703
Mean BMI for the respondents was 33.5 (+8.1). BMI values were categorized into a
weight status variable, with 12.3% of respondents in a normal BMI range (BMI between
18.5 and 24.9), 23.8% of respondents being overweight (BMI between 25 and 29.9), and
63.9% of respondents being obese (BMI of 30 or more). A dichotomous obesity status
variable was also calculated for use in analyses.
Based on the number of ER visits in the past one year obtained from hospital
medical records, it was observed that 72.2% of the respondents did not have a single ER
visit, 22.2% had between one and two ER visits, and the remaining 5.7% had more than
two ER visits in the past year. Based on the number of hospital admissions in the past
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one year obtained from hospital medical records, it was observed that 79.7% of
respondents had no hospitalizations, while 20.3% had at least one hospitalization in the
past year.
ICD-9 diagnoses information obtained from medical records was used to calculate
a Charlson comorbidity index for each respondent. The mean Charlson score was 1.18
(+2.56), with 62% of respondents having a score of zero. About 5% of respondents had
an ICD-9 diagnosis corresponding to renal complications due to diabetes, 40.9% had eye
complications due to diabetes, 10.7% had neurological complications due to diabetes, and
0.5% had peripheral vascular disease as a complication of diabetes. When a diabetes
complications score was calculated on the basis of presence of these complications,
50.8% of respondents had no such complication related to diabetes, while the remaining
49.2% had at least one such complication.

Quality of Life Variables
A total of 385 ADDQoL average weighted scores could be calculated. A negative
score on the ADDQoL would indicate that diabetes was negatively affecting QoL of the
individual, while a positive score would indicate a positive effect of diabetes. Intuitively,
a person with diabetes is expected to report a negative influence of the disease on his or
her QoL. At the same time, the bipolar scale allows for some respondents to have positive
scores, although these were expected to be uncommon. The mean of an overview item
assessing the impact of diabetes on QoL was -1.31(+1.00), while the average weighted
impact ADDQoL score that was calculated was found to be -1.95(+1.76). As shown in
Table 14, the maximum negative impact of diabetes was felt on ‘freedom to eat’,
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‘enjoyment of food’, and on ‘finances’, while diabetes least impacted ‘society reaction’,
‘dependence’, and ‘living conditions’. The mean ADDQoL average weighted scores
across demographic and medical history variables are shown in Table 15.
Upon transformation according to recommended procedures described in an
earlier section, a total of 348 PCS and MCS scores (on a 0-100 scale, where 0 represents
poorest general QoL) could be calculated. The mean PCS score was 45.54 (+12.30),
while the mean MCS score was 38.44 (+13.1). This is comparable to the estimates
presented in the scoring manual for PCS-12 and MCS-12 obtained from a U.S.
population with Type 2 diabetes with mean age of 57.6 years, 55.4% female respondents,
and with mean PCS score of 41.52 (+11.07) and mean MCS score of 47.28 (+ 10.72).
The mean PCS and MCS scores across demographic and medical history variables are
shown in Table 15.
No significant differences in respondents’ SF-PCS scores or SF-MCS scores were
found between the three clinic settings. There was a significant overall ANOVA for
difference in ADDQoL scores between the three clinic settings [F(2,374) = 3.16,
p = 0.044]; however post-hocs tests did not show any significant results. One-way
ANOVA also indicated that there were no significant differences in respondents’ average
A1C or recent A1C levels between the three clinics.
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Table 13: Demographic Profile of Respondents
Variable

N

%

< 60 years

182

47.3

> 60 years

202

52.5

Male

165

42.9

Female

220

57.1

47

12.2

Married/ with partner

238

61.8

Divorced/ separated

36

9.4

Widowed

59

15.3

White

361

93.8

Black

14

3.6

Asian

4

1.0

200

51.9

Some college/ vocational

85

22.1

College degree and beyond

93

24.2

28

7.3

State/ Federal insurance

223

57.9

Private insurance/ managed care

121

31.4

Excellent control

210

54.5

Good control

133

34.5

Marginal control

28

7.3

Poor control

13

3.4

2

0.5

Normal

44

11.4

Overweight

89

23.1

239

62.1

Age

Gender

Marital Status
Single

Race

Education
Less than high school

Insurance
No insurance

Glycemic control

Weight Status
Underweight

Obese

89

Mean (SD)

Variable

N

%

Mean (SD)

Treatment
Diet and exercise

29

7.5

189

49.1

36

9.4

122

31.7

No ER visits

278

72.2

1-2 ER visits

85

22.1

> 2 ER visits

22

5.7

307

79.7

78

20.3

0

195

50.6

1

167

43.4

22

5.8

Family Medicine

154

40.0

Medical General Practice

110

28.6

Endocrinology

121

31.4

Oral medications only
Insulin only
Oral medications and insulin
ER Utilization

Hospitalizations
No hospitalizations
At least one hospitalization
Diabetes Complication Score

>2
Patient’s Clinic

Charlson Comorbidity Score

1.18 (+2.56)

Duration of diabetes in years

10.17 (+9.10)

Recent A1C

7.20 (+1.40)

Average A1C

7.20 (+1.30)

SF-12 PCS

38.44 (+13.10)

SF-12 MCS

45.52 (+12.30)

ADDQoL weighted impact

-1.94 (+1.76)
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Table 14: Mean Weighted Impact Scores for ADDQoL Domains

Item no.

ADDQoL Domain

Mean (SD)

1

Working life

-1.73 (+2.52)

2

Family life

-2.17 (+2.720

3

Social life

-1.56 (+2.34)

4

Sex life

-1.60 (+2.64)

5

Physical Appearance

-1.33 (+2.3)

6

Physical activities

-2.16 (+2.67)

7

Holidays/ leisure

-1.75 (+2.47)

8

Travel

-1.84 (+2.51)

9

Confidence in ability

-1.67 (+2.48)

10

Motivation

-1.59 (+2.38)

11

Society reaction

-0.88 (+1.84)

12

Future

-2.13 (+3.34)

13

Finances

-2.20 (+2.90)

14

Dependence

-1.23 (+2.89)

15

Living Conditions

-1.32 (+2.31)

16

Freedom to eat

-3.10 (+3.04)

17

Enjoyment of food

-2.89 (+3.10)

18

Freedom to drink

-1.89 (+2.75)
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Table 15: Mean Scores on the ADDQoL, SF-PCS, and SF-MCS, and Significance of
Sub-group Differences

Variable

Mean (SD)

p

Mean (SD)

p

Mean (SD)

p

ADDQoL

value

SF-12 PCS

value

SF-12 MCS

value

Age

0.325

0.044*

0.000*

< 60 years

-2.04 (+1.78)

39.84 (+12.98)

42.61 (+12.55)

> 60 years

-1.86 (+1.74)

37.01 (+13.15)

48.54 (+11.33)

Gender

0.121

0.187

0.335

Male

-2.10 (+1.89)

39.52 (+13.11)

46.26 (+12.32)

Female

-1.82 (+1.65)

37.64 (+13.07)

44.97 (+12.30)

Marital Status

0.331

0.048*

0.044*

Single

-2.50 (+1.97)

37.19 (+12.54)

42.3 (+13.02)

Married/ with partner

-1.95 (+1.75)

39.83 (+13.09)

46.49 (+12.06)

Divorced/ separated

-1.79 (+1.91)

34.24 (+13.20)

41.87 (+12.48)

Widowed

-1.63 (+1.52)

36.18 (+13.21)

47.04 (+12.21)

Race

0.506

0.163

0.023*

White

-1.95 (+1.79)

38.02 (+13.02)

45.72 (+12.09)

Black

-2.44 (+1.00)

42.82 (+14.25)

44.33 (+13.80)

Asian

-1.53 (+0.67)

45.72 (+12.41)

46.36 (+9.38)

Education

< 0.000*

0.000*

0.159

Less than high school

-2.18 (+1.99)

36.65 (+11.89)

44.61 (+12.90)

Some college/ vocational

-1.84 (+1.59)

35.56 (+14.31)

44.99 (+12.27)

College degree and beyond

-1.60 (+1.29)

44.78 (+12.04)

47.64 (+11.23)

Insurance

0.012*

0.001*

0.257

No insurance

-2.50 (+2.16)

34.91 (+12.37)

42.54 (+13.71)

State/ Federal insurance

-1.08 (+1.91)

36.84 (+13.00)

45.16 (+12.50)

Pvt. insurance/ managed care

-1.59 (+1.30)

42.10 (+12.99)

46.68 (+11.73)

Glycemic control (average A1C)

0.164

0.526

0.220

Excellent control

-1.66 (+1.65)

39.44 (+13.08)

46.56 (+12.48)

Good control

-2.25 (+1.82)

37.21 (+13.21)

43.96 (+12.16)

Marginal control

-2.20 (+1.77)

38.52 (+12.17)

47.90 (+10.59)

Poor control

-2.23 (+2.20)

38.74 (+15.20)

44.71 (+13.01)
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Variable

Mean (SD)

p

Mean (SD)

p

Mean (SD)

p

ADDQoL

value

SF-12 PCS

value

SF-12 MCS

value

Weight Status

0.667

0.002*

0.002*

Underweight

-3.67

43.25

41.87

Normal

-1.99 (+1.77)

41.65 (+12.29)

51.57 (+9.15)

Overweight

-1.80 (+1.82)

42.24 (+12.43)

46.38 (+10.87)

Obese

-1.99 (+1.76)

36.36 (+12.94)

43.85 (+12.90)

Treatment

< 0.000*

0.009*

0.074

Diet and exercise

-1.19 (+1.03)

41.30 (+11.09)

43.70 (+14.00)

Oral medications only

-1.66 (+1.69)

40.22 (+13.10)

46.59 (+11.84)

Insulin only

-2.73 (+1.97)

35.95 (+14.90)

48.79 (+10.88)

Oral medications and insulin

-2.32 (+1.73)

35.41 (+12.2)

43.6 (+12.46)

ER Utilization

0.038*

0.000*

0.013*

No ER visits

-1.90 (+1.79)

40.11 (+13.10)

46.63 (+11.88)

1-2 ER visits

-1.85 (+1.67)

33.67 (+12.29)

43.12 (+12.99)

> 2 ER visits

-2.92 (+1.53)

35.07 (+11.34)

40.12 (+12.95)

Hospitalizations

0.083

0.000*

0.032*

No hospitalizations

-1.87 (+1.72)

39.99 (+12.9)

46.23 (+12.11)

At least one hospitalization

-2.26 (+1.89)

32.32 (+12.12)

42.71 (+12.74)

Diabetes Complication Score

0.005*

0.027*

0.082

0

-1.83 (+1.76)

40.13 (+13.15)

46.57 (+11.97)

1

-1.93 (+1.73)

37.11 (+12.78)

45.08 (+12.67)

2 or greater

-3.15 (+1.65)

33.78 (+13.25)

40.52 (+11.02)

Patient’s Clinic

0.044*

0.940

0.668

Family Medicine

-1.81 (+1.84)

38.18 (+14.02)

44.86 (+12.51)

Medical General Practice

-1.76 (+1.57)

38.80 (+13.01)

45.66 (+12.21)

Endocrinology

-2.27 (+1.79)

38.44 (+12.05)

46.24 (+12.20)

* significant at 0.05 level
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Results for Objective A

Factor Structure and Reliability of the ADDQoL
Since the developers of the ADDQoL (Bradley et al., 1999) have reported a onefactor structure, it was decided to perform a forced one-factor confirmatory factor
analysis in order to test the structure of the instrument from the data available from this
sample of patients. Three criteria were used: the a priori hypothesis that the measure was
uni-dimensional, the Scree plot, and the interpretability of the factor solution. Principal
components analysis was used to obtain a forced one-factor solution from the 18
weighted item scores of the ADDQoL, by specifying the number of factors to be
extracted as one regardless of their eigen values, rather than extracting all factors with an
eigen value greater than one. The KMO test of sampling adequacy (=0.9) and the
Bartlett’s test of sphericity (p < 0.000) indicated that the data was factor analyzable.
The Scree plot did not support the uni-dimensionality hypothesis, since there were
three factors with eigen values greater than one. No rotated solution was available since
the number of factors requested was one. The single factor explained 45.63% of the
variance from the 18 items of the ADDQoL. Factor loadings for each item on the single
unrotated factor showed that 15 items loaded greater than 0.5 on that factor; the factor
loadings for the other three items were 0.492, 0.481, and 0.375 respectively, as shown in
Table 16.
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Table 16: Loadings of ADDQoL Domains on the Single-Factor Solution

Item no.

ADDQoL Domain

Factor Loading

7

Holidays/ leisure

0.834

10

Motivation

0.820

9

Confidence in ability

0.810

8

Travel

0.805

6

Physical activities

0.773

3

Social life

0.730

2

Family life

0.722

15

Living Conditions

0.720

5

Physical Appearance

0.693

11

Society reaction

0.679

1

Working life

0.679

13

Finances

0.642

14

Dependence

0.613

12

Future

0.555

17

Enjoyment of food

0.507

16

Freedom to eat

0.492

4

Sex life

0.481

18

Freedom to drink

0.375
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Given the above results, it was decided to confirm the reliability of the ADDQoL
with the prevailing one-factor structure. The 18 ADDQoL weighted impact item scores
were analyzed for internal consistency using Cronbach’s alpha. The alpha coefficient
obtained was 0.92.
Given the internal consistency of the 18-item scale structure as discussed above, it
was decided to perform an unforced principal components factor analysis with Varimax
rotation, to study the loading of the individual items of the ADDQoL on the factors that
were noticed in the Scree plot discussed in the above analysis. This elicited three factors
with eigen values greater than 1 (8.213, 1.967, 1.132). The rotated component matrix
showed that the first factor comprised eight items of the ADDQoL, the second factor
comprised seven items, while the third factor comprised three items, with these factors
explaining 45.63%, 10.93%, and 6.29% of the total variance respectively. While the
items loading on the third factor (items 16 through 18) were items that concerned food
and drink-related activities, no broad description can be given to the eight items that
loaded on factor one (items 1 through 7 and 11), or to the seven items that loaded on
factor two (items 8, 9, 10, 12, 13, 14, and 15). Internal consistency reliability using
Cronbach’s alpha of the scale comprising the 7 items from factor two was found to be
0.87; for the scale comprising the 3 items from factor three it was 0.88.
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Construct Validity of the ADDQoL
T-tests revealed significantly poorer average weighted ADDQoL scores in the
insulin-treated group compared to the non-insulin treated group [t(372) = 3.98, p <
0.000). Further analyses revealed that the insulin treated group had significantly poorer
scores on the general QoL item, on the general item about the impact of diabetes on QoL,
and on the average weighted impact ADDQoL score (See Figure 1).
A one-way ANOVA was performed to calculate differences in average weighted
ADDQoL scores across diabetes treatment-related groups. The group reporting use of
both insulin and oral medications for their diabetes had the greatest negative impact of
diabetes on their QoL, followed by the group on insulin alone, the group on oral
medication only, and the group on diet and exercise alone, in that order, as seen
previously in Table 3. Overall F-test for this ANOVA was significant [F(3,364)= 7.787, p
< 0.000]. Post-hoc tests using the Bonferroni method revealed significantly lower
ADDQoL scores in the group on oral medications and insulin, as compared to the group
on oral medications alone. T-tests revealed significantly lower ADDQoL scores in the
group with A1Cs equal to or above 7.0 as compared to those with A1Cs below 7.0 [t(374)
= 3.13, p = 0.002].
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Figure 1: Impact of Diabetes on QoL as Reflected in ADDQoL Scores, by Insulin Use
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There were no significant differences in ADDQoL scores in patients who were
obese versus those who were not. The average weighted ADDQoL score correlated
significantly with diabetes complication score (Spearman r = -0.115, n=376, p = 0.025).
A one-way ANOVA on the categorized diabetes complications score (groups with 0, 1,
and 2 or more complications respectively) for differences in ADDQoL scores yielded a
significant overall F value [F(2,373) = 5.42, p = 0.005]. Post-hoc analysis using
Bonferroni correction revealed significantly lower ADDQoL scores for patients with two
or more complications compared to those with no complications (p = 0.003), and also
significantly lower ADDQoL scores for patients with two or more complications
compared to those with one complication (p = 0.008). On the other hand, no significant
correlation was found with the Charlson comorbidity index (Spearman r = -0.032, n =
376, p = 0.576). T-tests for differences in hospital visits was also not significant. A oneway ANOVA, testing for differences in ADDQoL scores between those who did not have
ER visits compared with those who had between one and 2 visits, and more than two
visits, were significant overall [F(2,374) = 3.30, p < 0.038]. Post-hoc analysis using
Bonferroni correction revealed significantly lower ADDQoL scores for patients with two
or more ER visits compared to those with no ER visits (p = 0.038), and also significantly
lower ADDQoL scores for patients with two or more ER visits, compared to those with
1-2 ER visits (p = 0.044).
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Factor Structure and Reliability of the SF-12
Since the SF-12 has an established two-factor structure, it was decided to perform
a forced two-factor confirmatory factor analysis in order to test the structure of the
instrument from the data available from this study. Three criteria were used: the a priori
hypothesis that the measure was bidimensional, the Scree plot, and the interpretability of
the factor solution. Principal components analysis was used to obtain a forced two-factor
solution from the z-scores of the eight SF-12 subscales, by specifying the number of
factors to be extracted as one regardless of their eigen values, rather than extracting all
factors with an eigen value greater than one. The z-scores for the eight SF-12 subscales
were generated in the course of scoring the SF-12 in order to obtain the SF-12 PCS and
the SF-12 MCS. In the process of scoring the SF-12, these z-scores were used in a
specified combination to produce aggregate physical and mental summary scores, which
were then finally transformed into the PCS and MCS. The KMO test of sampling
adequacy (=0.878) and the Bartlett’s test of sphericity (p < 0.000) indicated that the data
was factor analyzable.
The Scree plot supported the bidimensionality hypothesis; there were two factors
with eigen values greater than one (4.805, 1.003). The rotated component matrix showed
that both the factors comprised four subscales each. The subscales loading on the first
factor were physical functioning, role physical, bodily pain, general health, and vitality.
The subscales loading on the second factor were social functioning, role emotional and
mental general health. The two factors together explained 72.6% of the variance from the
z scores of the eight SF-12 subscales. Factor loadings for each subscale on the two factors
are shown in Table 17.
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Table 17: Loadings of SF-12 Domains on the Two-Factor Solution

SF-12ADDQoL Domain

Factor Loading
Factor 1

Factor 2

Physical Functioning Z Score

0.887

0.189

Role Physical Z Score

0.861

0.317

Bodily Pain Z Score

0.768

0.267

General Health Z Score

0.737

0.247

Vitality Z Score

0.601

0.494

Mental Health Z Score

0.113

0.919

Role Emotional Z Score

0.371

0.786

Social Functioning Z Score

0.480

0.617
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Given the above results, it was decided to confirm the internal consistency
reliability of the SF-12 with the prevailing two-factor structure, using Cronbach’s alpha.
The subscales loading on the two factors as explained above were each analyzed for
internal consistency using Cronbach’s alpha. The first factor, comprising the physical
functioning, role physical, bodily pain, general health, and vitality subscales showed a
Cronbach’s alpha coefficient of 0.85, while the second factor, comprising the social
functioning, role emotional and mental general health subscales showed a Cronbach’s
alpha coefficient of 0.80. Since the PCS and the MCS summary measures of the SF-12
are a linear combination of the eight domains measuring distinct health constructs (Ware,
Kosinki, Bowker and Gandek, 2002), measurement of the reliability of the PCS and MCS
subscales should take into account the interdependability of the domains. During
development, each item of the SF-12 was selected because it contained unique reliable
variance estimating physical or mental health, and the scoring algorithm provided in the
SF-12 scoring manual for the PCS and MCS is reflective of this.
Hence, it is necessary to take into account the reliability of each domain as well as
the covariances among them in estimating the reliability using the internal consistency
method (Nunnally and Bernstein, 1994). The method suggested in the SF-12 scoring
manual (Ware, Kosinki, Bowker and Gandek, 2002, p63) for the internal consistency
estimation for the instrument is based on this principle. Using this method, the
Cronbach’s alphas for SF PCS and the SF MCS were found to be 0.92 and 0.88,
respectively.
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Construct Validity of the SF-12
Both PCS and MCS were able to detect significantly lower QoL in patients with
Type 2 diabetes who were obese, compared with those who were not obese [t(335) =
3.96, p < 0.000 for PCS, and t(335) = 3.05, p = 0.002 for MCS]. The PCS score was
significantly negatively correlated to the Charlson comorbidity score (Pearson’s r = 0.193, n = 347, p < 0.000). Both the PCS and MCS scores were significantly lower in
patients who had one or more hospitalizations in the past one year, as compared to those
who did not have any such hospitalizations [t(346) = 4.5, p < 0.000 for PCS, and t(346) =
2.1, p = 0.032 for MCS]. One way ANOVAs, testing for differences in PCS and MCS
scores among those who did not have ER visits compared with those who had between
one and 2 visits, and more than two visits, were significant overall [F(2,345) = 7.96, p <
0.000 for PCS, and F(2,345) = 4.37, p = 0.013 for MCS].
Other tests were performed to compare the ability of the SF-12 to detect subgroup differences. T-tests revealed no significant differences in both PCS and MCS
scores based on level of glycemic control. T-tests revealed significantly poorer PCS
scores in the insulin-treated group compared to the non-insulin treated group [t(343) =
3.72, p < 0.000], but no such significant differences were found for MCS scores.
Similarly, a one-way ANOVA was performed to calculate difference in PCS score across
diabetes treatment-related groups. The overall F-test for this ANOVA, was significant
[F(3,335)= 3.96, p < 0.000]. The group reporting use of both insulin and oral medications
for their diabetes had the greatest negative impact of diabetes on their PCS score,
followed by the group on insulin alone, the group on oral medication only, and the group
on diet and exercise alone, in that order, as reported earlier. Post-hoc tests using the
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Bonferroni correction revealed significantly lower PCS scores in the group on oral
medications and insulin, as compared to the group on oral medications alone (p = 0.014).
No significant differences among diabetes treatment groups were found on MCS scores.
The PCS score was significantly lower in patients with at least one diabetes-related
complication [t (345) = 2.46, p = 0.014], but no significant differences were found for
MCS scores.

Results for Objective B

Hypothesis 1a
Given the nature of the scoring of the ADDQoL, a normal spread of scores and
normal distributions for the ADDQoL score cannot be expected. Spearman’s rank order
correlation coefficient between recent A1C and ADDQoL score was found to be
significant at -0.20 (n = 353, p < 0.000), while the correlation coefficient between
average A1C and ADDQoL score was also found to be significant at -0.19 (n = 376, p <
0.000).

Hypothesis 1b
There was no significant correlation between recent A1C and PCS scores of the
SF-12 (Spearman’s r = -0.06, n = 324, p = 0.276), and no significant correlation between
recent A1C and MCS scores of the SF-12 (Spearman’s r = -0.05, n = 324, p = 0.366).
Again, there was no significant correlation between average A1C and PCS scores of the
SF-12 (Spearman’s r = -0.047, n = 347, p = 0.388), and no significant correlation
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between average A1C and MCS scores of the SF-12 (Spearman’s r = -0.08, n = 347, p =
0.123).

Hypothesis 2
Hotelling’s t-test was used to test for the difference of two dependent correlations
from the same sample. The pairs of dependent correlations tested were: r(A1C,
ADDQoL) versus r(A1C, PCS), and r(A1C, ADDQoL versus r(A1C, MCS). These
comparisons were made for recent A1C levels as well as for average A1C levels. Only
those cases were considered where ADDQoL, PCS and MCS scores were available. For
recent A1Cs, the number of such cases was 319, while for average A1Cs, the number of
such cases was 342. The difference between the two dependent correlations was
considered significant at the 0.05 level if the value of the calculated t-statistic was >1.96,
and considered significant at the 0.01 level if the value of the calculated t-statistic was
> 2.16.
Using recent A1C levels, the difference in the correlations, r(A1C, ADDQoL)
versus r(A1C, PCS), was significant (t = -2.00, n = 319, p < 0.05); the difference in the
correlations, r(A1C, ADDQoL) versus r (A1C, MCS), was also significant (t = -2.6, n =
319, p < 0.05). Using respondents’ average A1C levels, the difference in the correlations,
r(A1C, ADDQoL) versus r(A1C, PCS), was significant (t = -2.05, n = 342, p < 0.05), but
the difference in the correlations, r(A1C, ADDQoL) versus r(A1C, MCS), was not
significant (t = -1.77, n = 342, p < 0.05).
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Hypothesis 3
Two sets of multiple regression analyses were conducted to predict ADDQoL
using the hierarchical regression technique. One set used average A1C as the primary
independent variable, while the second used recent A1C as the primary independent
variable. Race was not included as a predictor in the models since 94% of the respondents
were white, and other predictors were checked for the presence of multicollinearity. This
was important since there were multiple indicators of disease severity and health status
that were believed to influence QoL in some way. To further check for multicollinearity,
tolerance and variance inflation statistics were also requested while running all of the
regression analyses. Since multicollinearity was not detected in any of the regression
models, all predictors were included in the models.
Using average A1C:
The results of the hierarchical regression are presented in Tables 18 and 19. The
first block of variables, including average A1C, insulin use, complications score, and
duration of diabetes, increased the R2 by 6.0%, which was significant (F change = 4.79, p
= 0.001). Demographic variables introduced in the third block increased the R2 by 4.4%,
which was also significant (F change = 2.44, p = 0.026). The three models obtained
including additional blocks of variables, were all significant (See Table 18). The final
model had R2 = 0.13, adjusted R2 = 0.09, F(14, 290) = 3.18, p < 0.000. The significant
predictors in the final model were diabetes duration (p=0.05), number of ER visits in the
past year (p = 0.038), and age (p = 0.022) (See Table 19).
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Table 18: Summary of the Block-wise Entry of Predictors in the Hierarchical
Regression Model Predicting ADDQoL Scores Using Average A1C

Model

R Square

Adjusted R

R Square

F

Sig. F

F

Sig. F

Square

Change

Change

Change

Statistic

Statistic

1a

0.06

0.05

0.06

4.79

0.001

4.79

0.001

2

b

0.09

0.07

0.03

2.38

0.05

3.63

0.000

3

c

0.13

0.09

0.04

2.44

0.03

3.18

0.000

a.
b.
c.

Dependent Variable: ADDQoL average weighted impact score
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (average) category, Insulin use
status
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (average) category, Insulin use
status, Obesity Status, Charlson Comorbidity Score, Number of ER visits, Number of hospital visits
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (average) category, Insulin use
status, Obesity Status, Charlson Comorbidity Score, Number of ER visits, Number of hospital visits, Private
Insurance, Government insurance, Gender, Education, Marital status, Age
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Table 19: Results of the Hierarchical Regression Model Predicting ADDQoL Scores
Using Average A1C

Predictor

Beta

Variable

Std.

Test

Sig.

Error

statistic (t)

p

1.

A1C (average) category

-0.222

0.204

-1.09

0.269

2.

Insulin use

-0.305

0.230

-1.32

0.187

3.

Diabetes complications score

-0.180

0.153

-1.18

0.239

4.

Diabetes duration

-0.024*

0.012

-1.97

0.050

5.

Obesity status

-0.237

0.210

-1.13

0.260

6.

Charlson comorbidity score

0.071

0.047

1.50

0.134

7.

Number of hospital visits

-0.104

0.213

-0.49

0.625

8.

Number of ER visits

-0.162 *

0.077

-2.10

0.036

9.

Govt. insurance

0.310

0.373

0.83

0.406

10.

Pvt. insurance

0.737

0.383

1.93

0.055

11.

Age

0.492 *

0.214

2.30

0.022

12.

Gender

0.344

0.204

1.68

0.093

13.

Marital status

-0.096

0.210

-0.46

0.648

14.

Education

0.401

0.231

1.73

0.084

* significant at 0.05 level
Model fit statistics:
R2 = 0.13, adjusted R2 = 0.09, F(14, 290) = 3.18, p < 0.000
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Using recent A1C:
The results of the hierarchical regression are presented in Tables 20 and 21. The
first block of variables, including recent A1C, insulin use, complications score, and
duration of diabetes, increased the R2 by 6.2%, which was significant (F change = 4.64, p
= 0.001). Demographic variables introduced in the third block increased the R2 by 5.2%,
which was also significant (F change = 2.74, p = 0.013). The three models obtained
including additional blocks of variables were all significant. The final model had R2 =
0.14, adjusted R2 = 0.10, F(14, 270) = 3.17, p < 0.000 (See Table 20). The significant
predictors in the final model were number of ER visits in the past year (p = 0.049),
private insurance (p=0.025), and age (p = 0.017) (See Table 21).
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Table 20: Summary of the Block-wise Entry of Predictors in the Hierarchical
Regression Model Predicting ADDQoL Scores Using Recent A1C

Model

R Square

Adjusted R

R Square

F

Sig. F

F

Sig. F

Square

Change

Change

Change

Statistic

Statistic

1a

0.06

0.05

0.06

4.64

0.001

4.64

0.001

2

b

0.09

0.06

0.03

2.02

0.09

3.36

0.001

3

c

0.14

0.10

0.05

2.74

0.01

3.17

0.000

a.
b.
c.

Dependent Variable: ADDQoL average weighted impact score
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (recent) category, Insulin use
status
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (recent) category, Insulin use
status, Obesity Status, Charlson Comorbidity Score, Number of ER visits, Number of hospital visits
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (recent) category, Insulin use
status, Obesity Status, Charlson Comorbidity Score, Number of ER visits, Number of hospital visits, Private
Insurance, Government insurance, Gender, Education, Marital status, Age
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Table 21: Results of the Hierarchical Regression Model Predicting ADDQoL Scores
Using Recent A1C
Predictor

Beta

Variable

Std.

Test

Sig.

Error

statistic (t)

p

1.

A1C (average) category

-0.298

0.211

-1.41

0.159

2.

Insulin use

-0.229

0.238

-0.96

0.337

3.

Diabetes complications score

-0.151

0.159

-0.95

0.346

4.

Diabetes duration

-0.025

0.013

-1.93

0.055

5.

Obesity status

-0.243

0.218

-1.11

0.267

6.

Charlson comorbidity score

0.050

0.067

0.74

0.462

7.

Number of hospital visits

-0.107

0.224

-0.48

0.631

8.

Number of ER visits

-0.154 *

0.078

-1.98

0.049

9.

Govt. insurance

0.373

0.390

0.96

0.339

10.

Pvt. insurance

0.907*

0.402

2.26

0.025

11.

Age

0.548 *

0.224

2.40

0.017

12.

Gender

0.320

0.213

1.50

0.134

13.

Marital status

-0.063

0.219

-0.29

0.772

14.

Education

0.453

0.238

1.90

0.059

* significant at 0.05 level
Model fit statistics:
R2 = 0.14, adjusted R2 = 0.09, F(14, 270) = 3.17, p < 0.000
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Hypothesis 4 for SF PCS
Two sets of multiple regression analyses were conducted to predict SF PCS scores
using the hierarchical regression technique. As for hypothesis 3, one set used average
A1C as the primary independent variable, while the second used recent A1C as the
primary independent variable.
Using average A1C:
The results of the hierarchical regression are presented in Tables 22 and 23. The
first block of variables, including average A1C, insulin use, complications score, and
duration of diabetes, increased the R2 by 5.1%, which was significant (F change = 3.71, p
= 0.006). The second block of variables, including obesity status, Charlson comorbidity
score, number of hospital visits, number of ER visits increased the R2 by 11.2%, which
was also significant (F change = 9.04, p < 0.000). Demographic variables introduced in
the third block increased the R2 by 8.3%, which was also significant (F change = 4.86,
p < 0.000). The three models obtained including additional blocks of variables, were all
significant. The final model had R2 = 0.25, adjusted R2 = 0.21, F(14, 264) = 6.14,
p < 0.000 (See Table 22). The significant predictors in the final model were obesity status
(p < 0.000), number of hospital visits in the past year (p = 0.001), and education (p <
0.000) (See Table 23).
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Table 22: Summary of the Block-wise Entry of Predictors in the Hierarchical
Regression Model Predicting SF-PCS Scores Using Average A1C

Model

R Square

Adjusted R

R Square

F

Sig. F

F

Sig. F

Square

Change

Change

Change

Statistic

Statistic

1a

0.05

0.04

0.05

3.71

0.006

3.71

0.006

2

b

0.16

0.14

0.11

9.04

0.000

6.59

0.000

3

c

0.25

0.21

0.08

4.86

0.000

6.17

0.000

a.
b.
c.

Dependent Variable: SF PCS
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (average) category, Insulin use
status
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (average) category, Insulin use
status, Obesity Status, Charlson Comorbidity Score, Number of ER visits, Number of hospital visits
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (average) category, Insulin use
status, Obesity Status, Charlson Comorbidity Score, Number of ER visits, Number of hospital visits, Private
Insurance, Government insurance, Gender, Education, Marital status, Age
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Table 23: Results of the Hierarchical Regression Model Predicting SF-PCS Scores
Using Average A1C
Predictor

Beta

Variable

Std.

Test

Sig.

Error

statistic (t)

p

1.

A1C (average) category

0.947

1.524

0.62

0.535

2.

Insulin use

-2.317

1.733

-1.34

0.182

3.

Diabetes complications score

0.128

1.118

0.12

0.909

4.

Diabetes duration

-0.165

0.093

-1.78

0.077

5.

Obesity status

-6.278 *

1.565

-4.01

0.000

6.

Charlson comorbidity score

-0.345

0.355

-0.97

0.332

7.

Number of hospital visits

-5.044 *

1.556

-3.24

0.001

8.

Number of ER visits

-0.084

0.557

-0.15

0.879

9.

Govt. insurance

3.587

2.736

1.31

0.191

10.

Pvt. insurance

5.068

2.797

1.81

0.071

11.

Age

-2.815

1.607

-1.75

0.081

12.

Gender

-0.321

1.516

-0.21

0.832

13.

Marital status

1.266

1.565

0.81

0.419

14.

Education

6.917 *

1.702

4.06

0.000

* significant at 0.05 level
Model fit statistics:
R2 = 0.25, adjusted R2 = 0.21, F(14, 264) = 6.14, p < 0.000
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Using recent A1C:
The results of the hierarchical regression are presented in Tables 24 and 25. The
first block of variables, including recent A1C, insulin use, complications score, and
duration of diabetes increased the R2 by 4.2%, which was significant (F change = 2.78,
p = 0.027). The second block of variables, including obesity status, Charlson comorbidity
score, number of hospital visits, number of ER visits increased the R2 by 11.4%, which
was also significant (F change = 8.41, p < 0.000). Demographic variables introduced in
the third block increased the R2 by 8.5%, which was also significant (F change = 4.54,
p < 0.000). The three models obtained including additional blocks of variables, were all
significant. The final model had R2 = 0.24, adjusted R2 = 0.20, F(14, 244) = 5.51,
p < 0.000 (See Table 24). The significant predictors in the final model were obesity status
(p < 0.000), number of hospital visits in the past year (p = 0.009), education (p < 0.000),
and private health insurance (p = 0.044) (See Table 25).
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Table 24: Summary of the Block-wise Entry of Predictors in the Hierarchical
Regression Model Predicting SF-PCS Scores Using Recent A1C

Model

R Square

Adjusted R

R Square

F

Sig. F

F

Sig. F

Square

Change

Change

Change

Statistic

Statistic

1a

0.04

0.03

0.04

2.78

0.03

2.78

0.027

2

b

0.16

0.13

0.11

8.41

0.000

5.76

0.000

3

c

0.24

0.20

0.09

4.53

0.000

5.51

0.000

a.
b.
c.

Dependent Variable: SF PCS
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (recent) category, Insulin use
status
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (recent) category, Insulin use
status, Obesity Status, Charlson Comorbidity Score, Number of ER visits, Number of hospital visits
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (recent) category, Insulin use
status, Obesity Status, Charlson Comorbidity Score, Number of ER visits, Number of hospital visits Private
Insurance, Government insurance, Gender, Education, Marital status, Age
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Table 25: Results of the Hierarchical Regression Model Predicting SF-PCS Scores
Using Recent A1C
Predictor

Beta

Variable

Std.

Test

Sig.

Error

statistic (t)

p

1.

A1C (average) category

0.030

1.571

0.02

0.984

2.

Insulin use

-1.606

1.785

-0.90

0.369

3.

Diabetes complications score

0.883

1.157

0.76

0.446

4.

Diabetes duration

-0.156

0.096

-1.62

0.106

5.

Obesity status

-6.018 *

1.616

-3.72

0.000

6.

Charlson comorbidity score

-0.705

0.520

-1.36

0.177

7.

Number of hospital visits

-4.352*

1.643

-2.65

0.009

8.

Number of ER visits

-0.005

0.559

-0.10

0.924

9.

Govt. insurance

4.005

2.839

1.41

0.160

10.

Pvt. insurance

5.895 *

2.912

2.03

0.044

11.

Age

-1.873

1.681

-1.11

0.266

12.

Gender

-0.853

1.572

-0.54

0.588

13.

Marital status

0.741

1.621

0.46

0.648

14.

Education

7.081 *

1.749

4.05

0.000

* significant at 0.05 level
Model fit statistics:
R2 = 0.24, adjusted R2 = 0.20, F(14, 244) = 5.51, p < 0.000
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Hypothesis 4 for SF MCS
For the SF PCS, two sets of multiple regression analyses were conducted to
predict SF MCS scores using the hierarchical regression technique. One set used average
A1C as the primary independent variable, while the second used recent A1C as the
primary independent variable.
Using average A1C:
The results of the hierarchical regression are presented in Tables 26 and 27. The
first block of variables, including average A1C, insulin use, complications score, and
duration of diabetes increased the R2 by only 1.1%, which was not significant (F change =
0.782, p = 0.538). The second block of variables, including obesity status, Charlson
comorbidity score, number of hospital visits, number of ER visits increased the R2 by
5.5%, which was also significant (F change = 3.96, p = 0.004). Demographic variables
introduced in the third block increased the R2 by 6.9%, which was also significant (F
change = 3.52, p = 0.002). The models consisting of the second and third blocks, and
three blocks all together were significant [F(8,270) = 2.38, p = 0.017, and F(14,264) =
2.95, p < 0.000 respectively] . The final model had R2 = 0.14, adjusted R2 = 0.09,
F(14,264) = 2.95, p < 0.000 (See Table 26). The significant predictors in the final model
were obesity status (p = 0.014), and age (p < 0.000) (See Table 27).
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Table 26: Summary of the Block-wise Entry of Predictors in the Hierarchical
Regression Model Predicting SF-MCS Scores Using Average A1C
Model

R Square

Adjusted R

R Square

F

Sig. F

F

Sig. F

Square

Change

Change

Change

Statistic

Statistic

1

a

0.01

-0.003

0.01

0.78

0.538

0.78

0.538

2

b

0.07

0.04

0.06

3.96

0.004

2.39

0.017

3

c

0.14

0.09

0.07

3.52

0.002

2.95

0.000

a.
b.
c.

Dependent Variable: SF MCS
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (average) category, Insulin use
status
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (average) category, Insulin use
status, Obesity Status, Charlson Comorbidity Score, Number of ER visits, Number of hospital visits
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (average) category, Insulin use
status, Obesity Status, Charlson Comorbidity Score, Number of ER visits, Number of hospital visits, Private
Insurance, Government insurance, Gender, Education, Marital status, Age
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Table 27: Results of the Hierarchical Regression Model Predicting SF-MCS Scores
Using Average A1C
Predictor

Beta

Variable

Std.

Test

Sig.

Error

statistic (t)

p

1.

A1C (average) category

-0.678

1.556

-0.44

0.663

2.

Insulin use

0.221

1.769

0.13

0.901

3.

Diabetes complications score

-0.451

1.141

-0.40

0.693

4.

Diabetes duration

-0.008

0.095

-0.92

0.356

5.

Obesity status

-3.963 *

1.597

-2.48

0.014

6.

Charlson comorbidity score

0.362

0.362

1.00

0.319

7.

Number of hospital visits

-1.971

1.589

-1.24

0.216

8.

Number of ER visits

-0.747

0.568

-1.31

0.190

9.

Govt. insurance

1.637

2.793

0.59

0.558

10.

Pvt. insurance

4.381

2.855

1.54

0.126

11.

Age

6.628 *

1.640

4.04

0.000

12.

Gender

0.602

1.547

0.39

0.697

13.

Marital status

0.782

1.597

0.50

0.625

14.

Education

2.747

1.737

1.58

0.115

* significant at 0.05 level
Model fit statistics:
R2 = 0.14, adjusted R2 = 0.09, F(14, 264) = 2.95, p < 0.000

120

Using recent A1C:
The results of the hierarchical regression are presented in Tables 28 and 29. The
first block of variables, including recent A1C, insulin use, complications score, and
duration of diabetes increased the R2 by only 1.0%, which was not significant. The
second block of variables, including obesity status, Charlson comorbidity score, number
of hospital visits, number of ER visits increased the R2 by 7.4%, which was also
significant (F change = 4.30, p = 0.002). Demographic variables introduced in the third
block increased the R2 by 8.1%, which was also significant (F change = 3.88, p = 0.001).
The models consisting of the second and third blocks, and three blocks all together were
significant. The final model had R2 = 0.16, adjusted R2 = 0.11, F(14,244) = 3.19,
p < 0.000 (See Table 28). The significant predictors in the final model were obesity status
(p = 0.005) and age (p < 0.000) (See Table 29).
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Table 28: Summary of the Block-wise Entry of Predictors in the Hierarchical
Regression Model Predicting SF-MCS Scores Using Recent A1C

Model

R Square

Adjusted R

R Square

F

Sig. F

F

Sig. F

Square

Change

Change

Change

Statistic

Statistic

1a

0.01

-0.01

0.01

0.67

0.617

0.62

0.617

2

b

0.07

0.05

0.06

4.31

0.002

2.50

0.012

3

c

0.16

0.11

0.08

3.88

0.001

3.19

0.000

a.
b.
c.

Dependent Variable: SF MCS
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (recent) category, Insulin use
status
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (recent) category, Insulin use
status, Obesity Status, Charlson Comorbidity Score, Number of ER visits, Number of hospital visits
Predictors: (Constant), Diabetes duration, Diabetes Complications Score, A1C (recent) category, Insulin use
status, Obesity Status, Charlson Comorbidity Score, Number of ER visits, Number of hospital visits Private
Insurance, Government insurance, Gender, Education, Marital status, Age
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Table 29: Results of the Hierarchical Regression Model Predicting SF-MCS Scores
Using Recent A1C
Predictor

Beta

Variable

Std.

Test

Sig.

Error

statistic (t)

p

1.

A1C (average) category

-0.080

1.590

-0.05

0.961

2.

Insulin use

0.378

1.806

0.21

0.834

3.

Diabetes complications score

0.070

1.171

0.06

0.950

4.

Diabetes duration

-0.108

0.097

-1.11

0.270

5.

Obesity status

-4.581*

1.635

-2.80

0.005

6.

Charlson comorbidity score

-0.083

0.527

-0.16

0.874

7.

Number of hospital visits

-1.850

1.663

-1.11

0.267

8.

Number of ER visits

-0.792

0.565

-1.40

0.163

9.

Govt. insurance

2.193

2.872

0.76

0.446

10.

Pvt. insurance

5.412

2.946

1.84

0.067

11.

Age

7.104 *

1.701

4.18

0.000

12.

Gender

0.891

1.591

0.56

0.576

13.

Marital status

1.026

1.640

0.63

0.532

14.

Education

3.111

1.770

1.76

0.080

* significant at 0.05 level
Model fit statistics:
R2 = 0.16, adjusted R2 = 0.11, F(14, 244) = 3.19, p < 0.000

123

Power of the Study Results

The a priori power analyses conducted in order to ascertain the sample size
required for the statistical analyses in the study have been discussed in Chapter 3. Posthoc power analyses are conducted after a study has been completed in order to ascertain
whether the study had the necessary power to be able to make conclusions out of the
study findings. For this purpose, it is necessary to decide upon the alpha level for the
analysis, the sample size that was available for the analysis, and the effect size. With this
information, it is possible to ascertain the power of the study to detect this effect. Posthoc power analyses when conducted in this manner are sometimes termed as post-hoc
power analyses based on observed effects, or a posteriori power procedures.
However, there is a disagreement on whether post hoc power based on observed
effects can conclude whether a negative finding is truly negative, since observed power is
determined by the observed p-value. When the p-value is small, the post hoc power using
observed effects is large and when the p-value is large, the post hoc power is small
(Knapp, 1996). If the observed effects were not significant, a power analysis could state
that the study had the power to detect even a small effect, and that a non significant result
indicates that the effect is indeed zero (Zumbo and Hubley, 1998). Hence, the utility of
reporting an observed power calculation on reported effect has been questioned.
Opponents of post-hoc power calculations suggest the use of confidence intervals
in the place of post-hoc power calculations (Smith and Bates, 1992). Statisticians
convinced the American Psychological Association (APA) to this effect, and APA now
suggests the use of confidence intervals in is publications (Wilkinson, 1999). Confidence
intervals, the likely range of a true population value, give us an estimate of the amount of
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error involved in our data by telling us about the precision of the statistical estimates.
Confidence intervals are related to the concept of the power. The larger the confidence
interval, the less the precision in estimation (Hopkins, 2004), and the less power a study
has to detect differences between treatment conditions in experiments or between groups
of respondents in survey research. The lower (or numerically smaller) limit shows how
small the effect might be in the population; the upper limit shows how large the effect
might be (Hopkins, 2004). Another suggestion is to report the a priori power calculations
along with the confidence intervals. The discussion on power of the study results reported
in this section take into account these viewpoints.

Objective A
Results of the factor analysis of 18 life-domains of the ADDQoL and eight
domains of the SF-12 have been reported in an earlier section. Two standards were
considered to build power for the factor analyses of the QoL measures used: at least 10
cases required for each item and a subjects-to-variables ratio no lower than 5. Going by
both these recommendations, the study had the necessary sample size.

Objective B
Choosing a medium effect size (0.3) (Cohen, 1998) with a required power of 0.8
to 0.9, a required sample size of 64 to 111 was needed to perform correlation analyses.
This study met the sample size requirements for the correlation analyses.
Post-hoc power to detect the significant correlation between average A1C and
ADDQoL score (r = -0.20, n = 353, p < 0.000), was 0.99, while for the significant
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correlation between recent A1C and ADDQoL score (r = -0.19, n = 376, p < 0.000), posthoc power was 0.98. Due to the negligible and non-significant correlations between both
types of A1C levels and the SF PCS and SF MCS, post-hoc power analyses were not
conducted for these. The 95% confidence intervals for the correlations calculated for
hypotheses 1a and 1b are presented in Table 30.
For a set of predictors explaining 20% of the variance in the dependent variable
and with 14 predictors, a sample size of 84 was needed to achieve a power of 0.8 and 102
was needed to achieve a power of 0.9. For a set of predictors explaining 10% of the
variance in the dependent variable, and with 14 predictors, a sample size of 174 was
needed to achieve a power of 0.8 and 216 was needed to achieve a power of 0.9. With the
regression models used in the study explaining on an average 10% of the variance in
ADDQoL and MCS scores, and 20% of the variance in PCS scores, the sample size
requirements were met.
Post-hoc power calculations, testing the variance accounted for by the predictors
in the population QoL scores, involved the calculation of f2 from observed R2, after
inputting the number of predictors and deciding on an alpha level at 0.05. Observed
power for the hierarchical regression analyses reported in the study are presented in Table
31. All regression analyses had a post-hoc power greater than 0.9.
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Table 30: Bivariate Correlations and 95% Confidence Intervals for the Results of
Hypothesis 1
Variables

Bivariate

95%

correlation

Confidence Interval

A1C-average, ADDQoL score

r = -0.19, n = 376, p < 0.000

-0.285649, -0.090603

A1C-recent, ADDQoL score

r = -0.20, n = 353, p < 0.000

-0.29816 , -0.097654

A1C-average, SF-PCS score

r = -0.047, n = 347, p = 0.388

-0.151535, 0.058574

A1C-recent, SF-PCS score

r = -0.06, n = 324, p = 0.276

-0.167865, 0.049284

A1C-average, SF-MCS score

r = -0.08, n = 347, p = 0.123

-0.183737, 0.025499

A1C-recent, SF-MCS score

r = -0.05, n = 324, p = 0.366

-0.158101, 0.059285
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Table 31: Observed Power of the Hierarchical Regressions Models

Hypothesis

Model Description

3

Predicting ADDQoL score using avg. A1C
2

Observed power

0.95

2

R = 0.13, adjusted R = 0.09,
F(14, 290) = 3.18, p < 0.000

4

Predicting SF- PCS score using avg. A1C
2

0.99

2

R = 0.25, adjusted R = 0.21,
F(14, 264) = 6.14, p < 0.000

4

Predicting SF- MCS score using avg. A1C
2

0.93

2

R = 0.14, adjusted R = 0.09,
F(14,264) = 2.93, p < 0.000

3

Predicting ADDQoL score using recent A1C
2

0.94

2

R = 0.14, adjusted R = 0.09,
F(14, 270) = 3.08, p < 0.000

4

Predicting SF- PCS score using recent A1C
2

0.99

2

R = 0.24, adjusted R = 0.20,
F(14, 244) = 5.51, p < 0.000

4

Predicting SF- MCS score using recent A1C
2

2

R = 0.16, adjusted R = 0.11,
F(14,244) = 3.2, p < 0.000
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0.96

CHAPTER FIVE: DISCUSSION AND CONCLUSIONS

This chapter discusses the findings of each study hypothesis and draws conclusions. The
chapter also discusses the limitations of the study and makes recommendations for future
research.

Discussion for Objective A

The dimensionality, internal consistency, and construct validity of the SF-12 and
the ADDQoL in the study were assessed using the procedures detailed in the Chapter 3.

The ADDQoL in Type 2 Diabetes Patients
Given the high internal consistency reliability of the scale comprised of the 18
life-domains of the ADDQoL, the satisfactory factor loading of majority the 18 lifedomains on a single factor, and the substantial proportions of variance in all the items
explained by this factor, it was concluded to support the one-factor structure for the
ADDQoL. Type 2 diabetes patients with A1C levels above 7.0 had poorer QoL (as
indicated by lower ADDQoL scores) as compared to those with A1C levels equal to or
below 7.0. Also, insulin users were found to have significantly lower ADDQoL scores.
The average weighted ADDQoL score correlated significantly with the diabetes
complications score. This indicated greater negative impact of diabetes on QoL in people
with more diabetes-related complications. There was a significant difference in ADDQoL
scores between groups that had no ICD-9 diagnosis for diabetes-related complications
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versus those who had at least one such complication. Type 2 diabetes patients with a
greater number of diabetes-related complications had significantly poorer ADDQoL
scores as compared to those patients with no such complications. This supports the
construct validity of the ADDQoL. However, there was no significant association with
the Charlson comorbidity score, which is an index of general comorbid disease status. It
is possible that this was a result of the disease-specific nature of the ADDQoL.
There are other points that can make the case for the use of the ADDQoL to
assess the impact of diabetes on QoL. While Type 2 diabetes patients in the study
indicated an overall positive outlook towards life, the ADDQoL was able to detect a
negative influence of diabetes on their QoL. The ADDQoL has an overview item about
current general QoL, and was seen to be a good indicator of general health status. The
item showed a statistically significant positive correlation with the PCS and the MCS (r =
0.488, n = 344, p< 0.000 for PCS and r = 0.559, n = 344, p< 0.000 for MCS). This
general item was able to distinguish between obese and non-obese patients [t(363) = 3.45,
p = 0.001], and had a statistically significant negative correlation with the Charslon
comorbidity index (r = -0.123, n = 375, p< 0.017).
Both of these results were non-significant when the ADDQoL average weighted
score was used in place of the general QoL overview item. The overview item on general
QoL had a mean of 0.81 (+1.12). On the same scale, the mean of the second overview
item assessing the impact of diabetes on QoL was -1.31(+1.00), while the average
weighted impact ADDQoL score that was calculated was found to be-1.95(+1.76). Thus,
the ADDQoL could show how respondents’ general QoL differed from the overall impact
that diabetes had on their QoL. Also, this suggests that the domains included in the
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ADDQoL generate a total score that is able to further detect the negative effects that
diabetes has on various aspects of life, as reflected in the average weighted impact
ADDQoL score.

The SF-12 in Type 2 Diabetes Patients
Given the high percentage of variance explained by the forced two-factor
solution, and the strong factor loadings of the subscales on those factors, it was concluded
to support the two-factor structure for the SF-12. As indicated in an earlier section, five
subscales of the SF-12 were identified from confirmatory factor analysis to load on one
factor, while three subscales were identified to load on the second factor, and both the
subscales had high internal consistency reliability. From established research, the
subscale ‘vitality’ has been considered to load on the MCS, but the results from the first
part of the confirmatory factor analysis rather showed that the subscale loaded on the
PCS. This discrepancy can be explained by understanding that the PCS and the MCS
summary measures of the SF-12 are a linear combination of the eight domains measuring
distinct health constructs (Ware, Kosinki, Bowker and Gandek, 2002). During
development, each item of the SF-12 was selected because it contained unique reliable
variance estimating physical or mental health, and the scoring algorithm provided in the
SF-12 scoring manual for the PCS and MCS is reflective of this. Internal consistency
method of estimating reliability of the SF-12 sub scales using Cronbach’s alpha indicated
that the SF-PCS and the SF-MCS were both highly reliable.
The ADDQoL was unable to demonstrate any significant differences in QoL
between Type 2 diabetes patients who were obese versus those who were not. However,
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with the generic SF-12, both PCS and MCS indicated significantly poorer QoL in obese
patients. PCS score was significantly negatively correlated to the Charlson comorbidity
score, while both PCS and MCS scores were significantly lower in patients who had one
or more hospitalizations in the past one year, as compared to those who did not have any
such hospitalizations. Since PCS and MCS were indicated significant differences in QoL
between groups defined on the basis of these general health status indicators, the
construct validity of the SF-12 was supported. PCS scores were significantly lower in the
insulin-treated group as compared to the group not using insulin, as well as in the group
that had at least one ICD-9 diagnosis for a diabetes-related complication as compared to
the group that had none. This indicated sensitivity of the PCS to aspects of QoL related to
diabetes.

Discussion for Objective B

Hypothesis 1a
The null hypothesis that A1C level and ADDQoL score are not correlated was
rejected. The Spearman’s correlation was significant, and in a negative direction. This
result was true for both recent A1C levels as well as average A1C levels in the past year.
This indicates that as A1C level rises, QoL, as represented by low ADDQoL scores
declines in this sample of patients. However, the magnitude of the correlation was low,
suggesting a weak association between A1C and QoL.
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Hypothesis 1b
The null hypothesis that A1C level and PCS score of the SF-12 are not correlated
could not be rejected because the correlation between the two was not significant in this
sample of patients. Similarly, the null hypothesis that A1C level and MCS score of the
SF-12 are not correlated, could not be rejected.

Hypothesis 2
The null hypothesis was that there is no difference in the correlations between
A1C level and ADDQoL score, and A1C level and the PCS and MCS scores of the SF12. Using recent A1C levels, this hypothesis had to be rejected due to significant
differences in the correlations r(A1C, ADDQoL) versus r(A1C, PCS), as well as r(A1C,
ADDQoL) versus r(A1C, MCS), as shown by the significant Hotelling’s t-statistic. As
concluded for an earlier hypothesis, the association of QoL with A1C itself was weak.
Using average A1C levels, this hypothesis had to be rejected for the difference
between r(A1C, ADDQoL) versus r(A1C, PCS), due to significant Hotelling’s t-statistic.
However, we failed to reject the hypothesis of no significant difference in the correlations
r(A1C, ADDQoL) versus r(A1C, MCS).

Hypothesis 3
As mentioned in an earlier section, A1C was transformed into a dichotomous
variable based on the ADA’s recommended control level of an A1C of 7.0 or less. The
null hypothesis that A1C is not a significant predictor of ADDQoL scores could not be
rejected. A1C was not a significant predictor in all hierarchical regression models that
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were themselves significant. This was true for models using average A1C as the
independent variable (IV) of interest, as well as for models using recent A1C. Most
disease severity variables, including diabetes complications score, and insulin use status
were not significant predictors of ADDQoL scores. A summary of the regression models
predicting ADDQoL score, including model fit and significant variables, is presented in
Table 32. In hierarchical regression models, the predictors significantly influencing
ADDQoL scores were duration of diabetes, number of ER visits in the past year, health
insurance type, and age. Those people with Type 2 diabetes above 60 years of age,
having fewer number of ER visits in the past year, having fewer number of years of
diabetes, and having a private health insurance plan had significantly higher ADDQoL
scores.
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Table 32: Summary of Hierarchical Regression Models in Hypotheses 3 and 4

Hypothesis

Model

Significant Variables

Description
3

Predicting ADDQoL score

Number of ER visits

using average A1C

Age

2

2

R = 0.13, adjusted R = 0.09,

Diabetes duration

F(14, 290) = 3.18, p < 0.000

4

Predicting SF- PCS score

Obesity status

using average A1C

Number of hospital visits

R2 = 0.25, adjusted R2 = 0.21,

Education

F(14, 264) = 6.14, p < 0.000

4

Predicting SF- MCS score

Obesity status

using average A1C

Age

2

2

R = 0.14, adjusted R = 0.09,
F(14,264) = 2.95, p < 0.000

3

Predicting ADDQoL score

Number of ER visits

using recent A1C

Private Insurance

2

2

R = 0.14, adjusted R = 0.09,

Age

F(14, 270) = 3.17, p < 0.000

4

Predicting SF- PCS score

Obesity status

using recent A1C

Number of hospital visits

2

4

2

R = 0.24, adjusted R = 0.20,

Private Insurance

F(14, 244) = 5.51, p < 0.000

Education

Predicting SF- MCS score

Obesity status

using recent A1C

Age

2

2

R = 0.16, adjusted R = 0.11,
F(14,244) = 3.19, p < 0.000
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Hypothesis 4
A summary of the regression models predicting the SF-PCS score and the SFMCS score respectively, including model fit and significant variables, was presented in
Table 32. The null hypothesis that A1C is not a significant predictor of SF-12 PCS scores
and SF-12 MCS scores could not be rejected. A1C was not a significant predictor in all
hierarchical regression models that were themselves significant. This was true for models
using average A1C as the IV of interest, as well as for models using recent A1C. Obesity
status was a significant predictor of PCS and MCS scores in all models. Having a college
degree, not being obese, having fewer number of (or no) hospitalizations, and having a
private health insurance plan were significantly associated with higher PCS scores. Being
older than 60 years of age and not being obese were significantly associated with higher
MCS scores.
An overview discussion of the findings of the study is presented in the next
section.
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Overall Discussion of Findings

It is a generally accepted norm that larger study samples are better than smaller
samples (all other things being equal) because larger samples tend to minimize the
probability of errors, maximize the accuracy of population estimates, and increase the
generalizability of the results. Large sample sizes can produce a statistically significant
result even though there is limited or no practical importance associated with the finding.
In statistical significance testing, the p-value helps us draw conclusions about the
probability that the effect has any positive (or negative) value. If a statistically significant
negative effect is observed, then it can be said that the true value of the effect is likely to
be negative.
However, another viewpoint is that researchers should make conclusions about
the probability that the effect being tested is substantially positive (or negative), or in
other words, the probability of clinical or practical significance. When research is
published for use by clinicians in their practice, it is important to take into account the
probability that the effect being tested is large enough in magnitude to be termed
important in terms of its clinical implication. It may also be important to provide
information on the smallest possible value of the effect that may produce a clinically
pertinent outcome. On the other hand, clinicians reading such published work should also
understand the origin and interpretation of statistical significance.
The results of this study can also be examined through such contrasting
viewpoints. An A1C provides a more than a generally accurate and reliable method to
routinely assess the level of mean blood glucose and the relative level of diabetes control.
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A1C levels are also used to judge the effectiveness of treatment, and assess the risk for
development of possible acute and chronic complications typically associated with less
than optimal diabetes control. But when the outcome under consideration is a complex
construct like QoL, factors other than the effect of complications have to be studied.
Patients with Type 2 diabetes face a variety of issues pertaining to their physical,
emotional and social functioning, discussed in detail in an earlier section. Indeed, valid
and reliable instruments purporting to measure QoL in patients with diabetes will take
into account the impact of such factors associated with diabetes on QoL of patients.
Jenkinson (1994) suggested that patients’ perspectives can differ from what biomedical
measures may indicate in terms of their disease status. When translated to the present
study, this may mean that patients’ views on the condition of their life may differ from
what their A1Cs suggest. On another note, Bradley (2001) argues that if patients feel that
their health is poor, they may or may not perceive impairment in their QoL.
The results of the study suggest that A1C has a weak relationship with QoL, as
seen through the low magnitude of negative correlation between the two variables even
though the relationship was statistically significant. This could be explained by
suggesting that glycemic control status as represented by A1C may not be a symptomatic
indicator of the factors that influence the QoL of Type 2 diabetes patients. It is likely that
this relationship is being mediated through other variables that were studied and which
were seen to significantly influence QoL. Understanding these factors will help formulate
a treatment regimen that can not only optimize metabolic parameters but also QoL.
A diabetes-specific measure like the ADDQoL was able to detect differences in
the glycemic control status of patients with Type 2 diabetes in univariate analyses,
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something that the generic measure, the SF-12, could not. Considering that one of the
major goals of diabetes management is glycemic control, this may be an important
finding, although the association of QoL with A1C itself was weak, as indicated by the
results of the study. Most of the diabetes severity indicator variables (A1C, insulin use,
diabetes complications score) were not found to be significant predictors of the ADDQoL
score using hierarchical regression models. However, the number of ER visits in the past
year was found to significantly influence ADDQoL across regression models using recent
and average A1C, and duration of diabetes was found to be a significant predictor in the
model using average A1C. It can be thought that the effects of diabetes severity may
manifest themselves in acute health situations leading to ER visits. In this study, we
enumerated the number of diabetes complications based on ICD-9 classification; this
produced complication scores that may not be representative of the severity of
complications. Insulin users reported having diabetes for a significantly longer duration
than non-users [mean of 15.4 yrs. Vs mean of 6.6 yrs., t( 334) = -9.91, p < 0.000]. It is
possible that such insulin users have reconciled to themselves being on insulin and/ or
have learned to cope with the demands of treatment in a manner that it does not
significantly affect their current QoL. It may have been useful to collect information on
the number of years that Type 2 diabetes patients have been on insulin, to better explain
this.
Epidemiological research shows that a high percentage of patients with Type 2
diabetes tend to be obese, and 64% of respondents in this study were obese. But since
successive regression models showed that obesity status was not a significant predictor of
ADDQoL scores, it may be reasoned that many of the obese respondents have perceived
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their life to be in good standing as they manage their diabetes, and hence have high
scores on the ADDQoL. This could reflect on the ability of the ADDQoL average
weighted impact score to report the unique effects of diabetes QoL, by not being
confounded by the effects of other highly comorbid conditions like obesity. On the other
hand, it is likely that patients themselves did not perceive the factors associated with
obesity as influencing their QoL related to diabetes.
Regression models using generic QoL as the dependent variable conveyed just the
opposite, with non-obese respondents having significantly higher PCS and MCS scores,
after controlling for other factors. Number of hospital visits was another significant
predictor of PCS scores. Respondents with at least one hospitalization had a significantly
higher Charlson comorbidity index than those with no hospitalizations [3.06 Vs 0.7,
t(382) = -7.82, p < 0.00]. However, Charlson index and the number of hospitalizations
together as predictors in the model explaining QoL did not lead to a multicollinearity
situation, allowing the inclusion of both variables in the regression models. The Charlson
index gives greater importance to disease conditions that lead to mortality including a
large number of cardiovascular conditions, but it may not account for conditions
comorbid to diabetes that may also influence QoL, like depression and others.
In a recently published report of diabetes-related quality of care measures in a
national sample of 30 U.S. academic medical centers, 34.1% patients (including Type1
and Type 2 diabetes patients) were found to be at the recommended A1C goal of < 7%
(Grant, Buse and Meigs, 2005). In the same study, the mean A1C of patients in the
general medicine and endocrinology clinics was 8.1(+2.1) and 7.9(+1.8) respectively,
while the proportion of patients who were obese in the two clinics were 41.9% and 32.9%
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respectively. Results such as those presented here can be attributed to the unique nature
of the study sample. The patients in the current study, also from an academic medical
center in the state of West Virginia, and were in better glycemic control with a mean A1C
of 7.24 (+1.3); but the proportion of patients who were obese was much higher, at 62.1%.
About 55% of respondents were in excellent glycemic control, and another 33% were in
good control. To make accurate conclusions on the relationship between A1C and scores
on the ADDQoL and the SF-12, an adequate spread of data points on all these variables
would be desirable.
In hierarchical regression models, the same set of predictors were able to explain
a greater proportion of variance in PCS scores than ADDQoL scores. This may be a
result of the ability of the SF-12 to reflect the impairment of QoL due to the high
prevalence of comorbid obesity among the respondents with Type 2 diabetes. This result
can reflect on the basic structure of the two types of QoL instruments. The process of
item generation for QoL instruments is iterative; it uses a combination of theory, primary
data collection, and statistical analyses. Hence, the ADDQoL as it stands today consists
of questions that probe patients on a wide range of issues important to diabetes, and that
were decided upon from the process mentioned above. These items as a whole may be
unable to detect changes in diabetes QoL in a confounding condition of obesity within the
Type 2 diabetes population. On the other hand the SF-12, with dedicated physical and
mental health component summary scores, contains questions which may be sensitive to
the widespread comorbidity of obesity in the current study’s sample of Type 2 diabetes
patients.
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Study Limitations

All measurements in the study were planned and implemented to protect the
integrity of study results, but there were potential limitations inherent in the study design.
Limitations are discussed below:
The study employed a cross-sectional design that can establish associations
between the variables of interest at a single point in time, and has limited capability in
identifying any causal relationships.
Patients were recruited into the study at a convenience site, at the outpatient
clinics of a university hospital setting, limiting the generalizability of the study findings
to other settings.
Only patients with Type 2 diabetes were included in the study; however patients
with Type 1 diabetes are also affected by the management of the disease, but were not
contacted for the purpose of this study.
The study was an analysis of patients recruited from three different clinics:
Family Medicine, MGP and Endocrinology. Different levels of care in these clinics may
result in differences in QoL reported by patients.
It is likely that participation on the survey may be influenced by the nature of the
relationship between a patient and his/her physician.
Since this was a study of the QoL of patients with Type 2 diabetes in one period
in time, patients’ responses to the QoL questionnaire would have reflected his or her
views at that particular instant. Another point to consider is that individual QoL measures
ask questions on issues related to well being on different life domains as the respondent
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perceives them in a particular period of time. In the SF-12, this period is the previous four
weeks. The ADDQoL does not prescribe a definite time interval; it measures the ‘current’
effects of diabetes on QoL. Different patients may be dealing with different diabetesrelated issues at the time they respond to the QoL questionnaires. Some of the
respondents may have had the disease for many years and their responses could in some
way reflect their cumulative experiences in managing the disease. Others who are newly
diagnosed with the disease, may respond to the questionnaire with a different level and
type of experience in dealing with their diabetes.
Since the study primarily assessed the relationship between QoL and A1C (among
others), it was necessary to include those only patients for whom information on both
these variables was available. Results of the relationship between baseline QoL and
clinical values could be affected by specific patient characteristics. Importantly, there
were variances in the times at which patients had their lab values taken. The criteria used
in the sampling procedure discussed in the methods section was designed to address this
issue, although the same criteria may have caused an inadvertent inclusion of patients
who comply with physicians’ recommendation for having an A1C done. Patients who
generally do not would have been excluded. It is possible that those patients have poorer
glycemic control and the absence of their QoL and clinical data may indicate a bias in the
results.
Independent-samples t-tests analyses were performed to ascertain whether there
were differences in recent and average A1C levels between responders and nonresponders to our survey. There were no significant differences in recent A1C values
between the two groups. However, non-responders had significantly higher average A1C
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values [7.4(+1.56)] than responders [7.2(+1.30)] (p=0.041). It is not known whether this
difference in average A1C value between the two groups is clinically significant.
However, from this result it cannot be ruled out that Type 2 diabetes patients with better
average A1C values responded to our survey.
The study employed a single mail-out of a booklet of measures. Along with the
ADDQoL and the SF-12, different measures of interest to other researchers were
included. In keeping with prevailing trends about using multiple measures, the generic
SF-12 was been placed before the diabetes-specific ADDQoL. It is likely a respondent’s
answer may have been influenced by the answers to the previous measures, or by the
real-life situations discussed in earlier measures. In addition, the size of the booklet may
have imposed some respondent burden, discouraging some patients from responding
completely or accurately.
The study incorporates medical history variables and health status indicators that
were obtained from administrative databases and medical chart reviews. The study may
be influenced by errors in coding these secondary databases.
Quality of life measured in the course of the study is a self-reported measure.
Patients responding to the QoL questionnaires may tend to give socially desirable
responses. Some patients may provide answers that they perceive will reflect positively
on them, while on the other hand, other patients may report answers that they perceive
will reflect extreme hardships they face. Thus, patients could have provided biased
responses in a QoL survey.
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Study Conclusions

In the assessment of QoL, we are faced with a selection between generic and
disease-specific measures, or using both types of measures to complement each other.
The study indicates the utility of the ADDQoL and the SF-12 scores in performing QoL
assessments in populations with Type 2 diabetes, and confirms the construct validity and
reliability of thee instruments. The complementary use of a generic QoL measure along
with a diabetes-specific measure seems essential in view of the high prevalence of the
comorbid obesity.
The results of the study suggest that the A1C has a weak relationship with QoL.
This provides evidence that patients’ perspectives may be different from what a
biomedical indicator like A1C may indicate in terms of glycemic control.

Directions for Future Research

Quality of life is a complex psychosocial concept, and patients with diabetes are
affected by many issues in the day-to-day management of the disease. The study
attempted to take this into account by collecting data on variables that were
representative of these issues. Hence demographic, medical history, and health status and
disease severity variables were collected to explain the way they may influence QoL.
Apart from the objective collection of diabetes severity indicators from medical
records, subjective indices can be calculated. This can be done by using physicians’
opinions on the extent of severity of a diabetes complication, and calculating a weighted
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complications score. Other indicators of disease severity include indices based on
prescription drug use and insulin dosage. Additionally, it may be useful to obtain
information on the duration of insulin usage in Type 2 diabetes patients.
There are other psychosocial indicators that could contribute to a greater
understanding of the QoL of patients with Type 2 diabetes. This includes variables
describing the engagement of patients in diabetes self-management behaviors
recommended by their healthcare providers, and the coping styles that patients embrace
in facing the situations arising from their diabetes. Self-report of depressive symptoms
may also help explain why patients may not adhere to recommended behaviors. Future
studies could measure these variables and assess the extent to which they add to the
explanatory power of regression models with diabetes-specific QoL as the dependent
variable.
It is likely that all of these factors influence QoL through interdependent
pathways that mediate the effect of other variables on QoL. Some of these relations have
been proposed in the discussions section. A statistical technique that can test these
interdependent relationships is path analysis, which requires an a priori model depicting
hypothesized relationships among different sets of variables as they influence QoL in
diabetes patients. While the whole model can be tested for adequacy of fit with the
observed data, individual direct relationships between variables can be tested for their
significance, including mediating pathways.
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Appendix C: Reminder Card

November, 2004
Dear Patient,
Last week a questionnaire concerning the care of people with diabetes was mailed to you
along with a letter from your physician or care provider. We hope you found the topic of
interest and importance.
If you have already returned the questionnaire, we thank you very much for your help.
We know you are busy. Information that you and others provide will be used to help
develop solutions for problems identified. If you have not yet filled out the questionnaire,
it is hoped you will find a few minutes over the next few days for this. Your participation
is entirely voluntary, but we feel it is essential to the quality of the study. Please note that
all information will be kept as confidential as legally possible.
If you did not receive a letter from your physician containing the questionnaire packet, or
have misplaced it, please contact Dr. Jan Kavookjian at WVU 304-293-1453 and another
will be sent out right away.
Again, thank you very much for your assistance.
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